drug1_db stringlengths 7 7 | drug2_db stringlengths 7 7 | drug1_id int64 0 1.69k | drug2_id int64 0 1.69k | drug_pair listlengths 2 2 | drug1_name stringlengths 4 85 | drug2_name stringlengths 4 85 | drug1_desc stringlengths 27 1.09k | drug2_desc stringlengths 27 6.14k | label stringclasses 3
values | label_idx int64 0 2 | all_paths listlengths 1 10 | all_paths_str listlengths 1 10 | path_str stringlengths 0 3.57k |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
DB08880 | DB08901 | 1,510 | 1,468 | [
"DDInter1771",
"DDInter1492"
] | Teriflunomide | Ponatinib | Teriflunomide is the active metabolite of leflunomide, and it acts as an immunomodulatory agent by inhibiting pyrimidine synthesis. It is marketed under the name Aubagio® and is indicated for the treatment of multiple sclerosis, specifically relapsing forms. The FDA label states an important warning about the risk of h... | Ponatinib is a novel Bcr-Abl tyrosine kinase inhibitor that is especially effective against the T315I mutation for the treatment of chronic myeloid leukemia. FDA approved on December 14, 2012. | Major | 2 | [
[
[
1510,
25,
1468
]
],
[
[
1510,
64,
478
],
[
478,
24,
1468
]
],
[
[
1510,
63,
752
],
[
752,
23,
1468
]
],
[
[
1510,
24,
987
],
[
987,
... | [
[
[
"Teriflunomide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ponatinib"
]
],
[
[
"Teriflunomide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Nilotinib"
],
[
"Nilotinib",
"{u... | Teriflunomide may lead to a major life threatening interaction when taken with Nilotinib and Nilotinib may cause a moderate interaction that could exacerbate diseases when taken with Ponatinib
Teriflunomide may cause a moderate interaction that could exacerbate diseases when taken with Cimetidine and Cimetidine may cau... |
DB00067 | DB00398 | 317 | 79 | [
"DDInter1921",
"DDInter1702"
] | Vasopressin | Sorafenib | Vasopressin (arginine-vasopressin or antidiuretic hormone) is a nonapeptide primarily produced in the hypothalamus that exhibits diverse physiological functions related to diuresis, hemodynamic modulation, and behaviour.[A110, A111, A112, A113, A228008] Vasopressin is very similar to oxytocin, differing in the third an... | Sorafenib is a bi-aryl urea and an oral multikinase inhibitor. It targets cell surface tyrosine kinase receptors and downstream intracellular kinases that are implicated in tumour cell proliferation and tumour angiogenesis. First approved by the FDA and European Commission in 2007 for the treatment of hepatocellular ca... | Moderate | 1 | [
[
[
317,
24,
79
]
],
[
[
317,
23,
112
],
[
112,
62,
79
]
],
[
[
317,
24,
543
],
[
543,
63,
79
]
],
[
[
317,
63,
521
],
[
521,
24,
... | [
[
[
"Vasopressin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sorafenib"
]
],
[
[
"Vasopressin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
[
... | Vasopressin may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Sorafenib
Vasopressin may cause a moderate interaction that could exacerbate diseases when taken with Loperamide and Lop... |
DB00446 | DB01253 | 597 | 628 | [
"DDInter351",
"DDInter664"
] | Chloramphenicol | Ergometrine | An antibiotic first isolated from cultures of _Streptomyces venezuelae_ in 1947 but now produced synthetically. It has a relatively simple structure and was the first broad-spectrum antibiotic to be discovered. It acts by interfering with bacterial protein synthesis and is mainly bacteriostatic. (From Martindale, The E... | An ergot alkaloid with uterine and vascular smooth muscle contractile properties. | Moderate | 1 | [
[
[
597,
24,
628
]
],
[
[
597,
63,
1131
],
[
1131,
40,
628
]
],
[
[
597,
24,
826
],
[
826,
40,
628
]
],
[
[
597,
6,
8374
],
[
8374,
... | [
[
[
"Chloramphenicol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ergometrine"
]
],
[
[
"Chloramphenicol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Methysergide"
... | Chloramphenicol may cause a moderate interaction that could exacerbate diseases when taken with Methysergide and Methysergide (Compound) resembles Ergometrine (Compound)
Chloramphenicol may cause a moderate interaction that could exacerbate diseases when taken with Ergotamine and Ergotamine (Compound) resembles Ergomet... |
DB00945 | DB00978 | 1,479 | 739 | [
"DDInter20",
"DDInter1084"
] | Acetylsalicylic acid | Lomefloxacin | Also known as _Aspirin_, acetylsalicylic acid (ASA) is a commonly used drug for the treatment of pain and fever due to various causes. Acetylsalicylic acid has both anti-inflammatory and antipyretic effects. This drug also inhibits platelet aggregation and is used in the prevention of blood clots stroke, and myocardial... | Lomefloxacin is a fluoroquinolone antibiotic, used to treat bacterial infections including bronchitis and urinary tract infections (UTIs). Additionally, it has been employed for the prophylaxis of UTIs prior to surgery as well. | Moderate | 1 | [
[
[
1479,
24,
739
]
],
[
[
1479,
24,
945
],
[
945,
40,
739
]
],
[
[
1479,
63,
1176
],
[
1176,
1,
739
]
],
[
[
1479,
63,
1467
],
[
1467,
... | [
[
[
"Acetylsalicylic acid",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lomefloxacin"
]
],
[
[
"Acetylsalicylic acid",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sparf... | Acetylsalicylic acid may cause a moderate interaction that could exacerbate diseases when taken with Sparfloxacin and Sparfloxacin (Compound) resembles Lomefloxacin (Compound)
Acetylsalicylic acid may cause a moderate interaction that could exacerbate diseases when taken with Moxifloxacin and Moxifloxacin (Compound) re... |
DB00502 | DB00687 | 1,300 | 870 | [
"DDInter853",
"DDInter747"
] | Haloperidol | Fludrocortisone | Haloperidol is a high potency first-generation (typical) antipsychotic and one of the most frequently used antipsychotic medications used worldwide. While haloperidol has demonstrated pharmacologic activity at a number of receptors in the brain, it exerts its antipsychotic effect through its strong antagonism of the do... | Fludrocortisone is a synthetic mineralocorticoid used in conjunction with [hydrocortisone] to replace missing endogenous corticosteroids in patients with adrenal insufficiency.[A187169,A187187] It is functionally similar to [aldosterone], the body's primary endogenous mineralocorticoid, and is structurally analogous to... | Moderate | 1 | [
[
[
1300,
24,
870
]
],
[
[
1300,
24,
167
],
[
167,
40,
870
]
],
[
[
1300,
21,
28835
],
[
28835,
60,
870
]
],
[
[
1300,
24,
688
],
[
688,
... | [
[
[
"Haloperidol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fludrocortisone"
]
],
[
[
"Haloperidol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Hydrocortisone"
... | Haloperidol may cause a moderate interaction that could exacerbate diseases when taken with Hydrocortisone and Hydrocortisone (Compound) resembles Fludrocortisone (Compound)
Haloperidol (Compound) causes Hyperglycaemia (Side Effect) and Hyperglycaemia (Side Effect) is caused by Fludrocortisone (Compound)
Haloperidol ma... |
DB12267 | DB14881 | 1,476 | 180 | [
"DDInter233",
"DDInter1329"
] | Brigatinib | Oliceridine | Brigatinib, originally named AP26113, is a reversible dual inhibitor of anaplastic lymphoma kinase (ALK) and epidermal growth factor receptor (EGFR). It presents selectivity against the mutant forms of EGFR compared to the wild-type. It also exhibits selectivity against 9 different Crizotinib-resistant mutants of the E... | Severe acute pain occurs through nociceptive signalling involving both ascending and descending spinal pathways, in which nerve conductance is mediated in part by the action of opioid receptors.[A218041, A218046] Opioid receptors are seven-transmembrane G-protein-coupled receptors (GPCRs), of which the μ-opioid recepto... | Moderate | 1 | [
[
[
1476,
24,
180
]
],
[
[
1476,
63,
1094
],
[
1094,
24,
180
]
],
[
[
1476,
64,
375
],
[
375,
24,
180
]
],
[
[
1476,
24,
1619
],
[
1619,
... | [
[
[
"Brigatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Oliceridine"
]
],
[
[
"Brigatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Metreleptin"
],
[
... | Brigatinib may cause a moderate interaction that could exacerbate diseases when taken with Metreleptin and Metreleptin may cause a moderate interaction that could exacerbate diseases when taken with Oliceridine
Brigatinib may lead to a major life threatening interaction when taken with Certolizumab pegol and Certolizum... |
DB00559 | DB00620 | 152 | 175 | [
"DDInter223",
"DDInter1855"
] | Bosentan | Triamcinolone | Bosentan is a dual endothelin receptor antagonist marketed under the trade name Tracleer by Actelion Pharmaceuticals. Bosentan is used to treat pulmonary hypertension by blocking the action of endothelin molecules that would otherwise promote narrowing of the blood vessels and lead to high blood pressure. | Triamcinolone is a corticosteroid used to treat various inflammatory conditions in the body from allergic rhinitis to acute exacerbations of multiple sclerosis. Triamcinolone can be used as a one time adjunct treatment of osteoarthritic knee pain, or first line as a topical treatment of corticosteroid responsive dermat... | Moderate | 1 | [
[
[
152,
24,
175
]
],
[
[
152,
24,
1573
],
[
1573,
1,
175
]
],
[
[
152,
63,
251
],
[
251,
1,
175
]
],
[
[
152,
6,
8374
],
[
8374,
45... | [
[
[
"Bosentan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Triamcinolone"
]
],
[
[
"Bosentan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Prednisone"
],
[
... | Bosentan may cause a moderate interaction that could exacerbate diseases when taken with Prednisone and Prednisone (Compound) resembles Triamcinolone (Compound)
Bosentan may cause a moderate interaction that could exacerbate diseases when taken with Betamethasone and Betamethasone (Compound) resembles Triamcinolone (Co... |
DB00488 | DB00501 | 196 | 752 | [
"DDInter57",
"DDInter380"
] | Altretamine | Cimetidine | An alkylating agent proposed as an antineoplastic. It also acts as a chemosterilant for male houseflies and other insects. | A histamine congener, it competitively inhibits histamine binding to histamine H2 receptors. Cimetidine has a range of pharmacological actions. It inhibits gastric acid secretion, as well as pepsin and gastrins output. It also blocks the activity of cytochrome P-450 which might explain proposals for use in neoadjuvant ... | Moderate | 1 | [
[
[
196,
24,
752
]
],
[
[
196,
21,
28784
],
[
28784,
60,
752
]
],
[
[
196,
24,
759
],
[
759,
62,
752
]
],
[
[
196,
63,
1023
],
[
1023,
... | [
[
[
"Altretamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cimetidine"
]
],
[
[
"Altretamine",
"{u} (Compound) causes {v} (Side Effect)",
"Thrombocytopenia"
],
[
"Thrombocytopenia",
"{u} (Side... | Altretamine (Compound) causes Thrombocytopenia (Side Effect) and Thrombocytopenia (Side Effect) is caused by Cimetidine (Compound)
Altretamine may cause a moderate interaction that could exacerbate diseases when taken with Primidone and Primidone may cause a minor interaction that can limit clinical effects when taken ... |
DB00651 | DB01226 | 746 | 1,319 | [
"DDInter613",
"DDInter1235"
] | Dyphylline | Mivacurium | Dyphylline is a theophylline derivative with broncho- and vasodilator properties. It is typically used in the management of asthma, cardiac dyspnea, and bronchitis. | Mivacurium is a bisbenzylisoquinolinium based neuromuscular blocker or muscle relaxant. It binds competitively to cholinergic receptors on the motor end-plate to antagonize the action of acetylcholine, resulting in a block of neuromuscular transmission. | Moderate | 1 | [
[
[
746,
24,
1319
]
],
[
[
746,
24,
648
],
[
648,
1,
1319
]
],
[
[
746,
21,
29118
],
[
29118,
60,
1319
]
],
[
[
746,
40,
1031
],
[
1031,
... | [
[
[
"Dyphylline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mivacurium"
]
],
[
[
"Dyphylline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Doxacurium"
],
[
... | Dyphylline may cause a moderate interaction that could exacerbate diseases when taken with Doxacurium and Doxacurium (Compound) resembles Mivacurium (Compound)
Dyphylline (Compound) causes Tachycardia (Side Effect) and Tachycardia (Side Effect) is caused by Mivacurium (Compound)
Dyphylline (Compound) resembles Theophyl... |
DB00530 | DB09280 | 1,195 | 1,604 | [
"DDInter667",
"DDInter1101"
] | Erlotinib | Lumacaftor | Erlotinib is an inhibitor of the epidermal growth factor receptor (EGFR) tyrosine kinase that is used in the treatment of non-small cell lung cancer, pancreatic cancer and several other types of cancer. It is typically marketed under the trade name Tarceva. Erlotinib binds to the epidermal growth factor receptor (EGFR)... | Lumacaftor is a drug used in combination with as the fixed dose combination product Orkambi for the management of Cystic Fibrosis (CF) in patients aged 6 years and older. Cystic Fibrosis is an autosomal recessive disorder caused by one of several different mutations in the gene for the Cystic Fibrosis Transmembrane Con... | Moderate | 1 | [
[
[
1195,
24,
1604
]
],
[
[
1195,
25,
379
],
[
379,
24,
1604
]
],
[
[
1195,
24,
1468
],
[
1468,
24,
1604
]
],
[
[
1195,
64,
837
],
[
837,
... | [
[
[
"Erlotinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lumacaftor"
]
],
[
[
"Erlotinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Rabeprazole"
],
[
"Rabeprazole... | Erlotinib may lead to a major life threatening interaction when taken with Rabeprazole and Rabeprazole may cause a moderate interaction that could exacerbate diseases when taken with Lumacaftor
Erlotinib may cause a moderate interaction that could exacerbate diseases when taken with Ponatinib and Ponatinib may cause a ... |
DB00512 | DB01357 | 91 | 890 | [
"DDInter1916",
"DDInter1160"
] | Vancomycin | Mestranol | Antibacterial obtained from Streptomyces orientalis. It is a glycopeptide related to ristocetin that inhibits bacterial cell wall assembly and is toxic to kidneys and the inner ear. As of January 29 2018, CutisPharma's Firvanq is the only FDA approved vancomycin oral liquid treatment option available for the the treatm... | The 3-methyl ether of ethinyl estradiol. It must be demethylated to be biologically active. It is used as the estrogen component of many combination ORAL contraceptives. | Moderate | 1 | [
[
[
91,
24,
890
]
],
[
[
91,
24,
1438
],
[
1438,
1,
890
]
],
[
[
91,
24,
50
],
[
50,
24,
890
]
],
[
[
91,
24,
1096
],
[
1096,
25,
... | [
[
[
"Vancomycin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mestranol"
]
],
[
[
"Vancomycin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Estradiol"
],
[
... | Vancomycin may cause a moderate interaction that could exacerbate diseases when taken with Estradiol and Estradiol (Compound) resembles Mestranol (Compound)
Vancomycin may cause a moderate interaction that could exacerbate diseases when taken with Sulfasalazine and Sulfasalazine may cause a moderate interaction that co... |
DB06595 | DB14881 | 1,491 | 180 | [
"DDInter1214",
"DDInter1329"
] | Midostaurin | Oliceridine | Midostaurin (as Rydapt) is a multitarget kinase inhibitor for the treatment for adult patients with newly diagnosed acute myeloid leukemia (AML) who have a specific genetic mutation called FLT3. It was initially characterized as a potential broad-spectrum antineoplastic agent, with activity toward diverse solid and hem... | Severe acute pain occurs through nociceptive signalling involving both ascending and descending spinal pathways, in which nerve conductance is mediated in part by the action of opioid receptors.[A218041, A218046] Opioid receptors are seven-transmembrane G-protein-coupled receptors (GPCRs), of which the μ-opioid recepto... | Moderate | 1 | [
[
[
1491,
24,
180
]
],
[
[
1491,
62,
112
],
[
112,
23,
180
]
],
[
[
1491,
63,
401
],
[
401,
24,
180
]
],
[
[
1491,
24,
1094
],
[
1094,
... | [
[
[
"Midostaurin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Oliceridine"
]
],
[
[
"Midostaurin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
... | Midostaurin may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Oliceridine
Midostaurin may cause a moderate interaction that could exacerbate diseases when taken with Promethazine and... |
DB00502 | DB00804 | 1,300 | 1,507 | [
"DDInter853",
"DDInter543"
] | Haloperidol | Dicyclomine | Haloperidol is a high potency first-generation (typical) antipsychotic and one of the most frequently used antipsychotic medications used worldwide. While haloperidol has demonstrated pharmacologic activity at a number of receptors in the brain, it exerts its antipsychotic effect through its strong antagonism of the do... | Dicyclomine is a muscarinic M1, M3, and M2 receptor antagonist as well as a non-competitive inhibitor of histamine and bradykinin used to treat spasms of the intestines seen in functional bowel disorder and irritable bowel syndrome.[A6556,A182555,A234659,L7967] Though it is commonly prescribed, its recommendation may h... | Moderate | 1 | [
[
[
1300,
24,
1507
]
],
[
[
1300,
6,
9842
],
[
9842,
45,
1507
]
],
[
[
1300,
21,
29231
],
[
29231,
60,
1507
]
],
[
[
1300,
63,
1594
],
[
1... | [
[
[
"Haloperidol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dicyclomine"
]
],
[
[
"Haloperidol",
"{u} (Compound) binds {v} (Gene)",
"CYP1A1"
],
[
"CYP1A1",
"{u} (Gene) is bound by {v} (Compound... | Haloperidol (Compound) binds CYP1A1 (Gene) and CYP1A1 (Gene) is bound by Dicyclomine (Compound)
Haloperidol (Compound) causes Cardiac disorder (Side Effect) and Cardiac disorder (Side Effect) is caused by Dicyclomine (Compound)
Haloperidol may cause a moderate interaction that could exacerbate diseases when taken with ... |
DB01309 | DB04575 | 1,254 | 35 | [
"DDInter933",
"DDInter1555"
] | Insulin glulisine | Quinestrol | Insulin glulisine is a short-acting form of insulin used for the treatment of hyperglycemia caused by Type 1 and Type 2 Diabetes. Insulin is typically prescribed for the management of diabetes mellitus to mimic the activity of endogenously produced human insulin, a peptide hormone produced by beta cells of the pancreas... | The 3-cyclopentyl ether of ethinyl estradiol. | Moderate | 1 | [
[
[
1254,
24,
35
]
],
[
[
1254,
63,
566
],
[
566,
1,
35
]
],
[
[
1254,
24,
984
],
[
984,
40,
35
]
],
[
[
1254,
63,
1336
],
[
1336,
4... | [
[
[
"Insulin glulisine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Quinestrol"
]
],
[
[
"Insulin glulisine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Levonorgestre... | Insulin glulisine may cause a moderate interaction that could exacerbate diseases when taken with Levonorgestrel and Levonorgestrel (Compound) resembles Quinestrol (Compound)
Insulin glulisine may cause a moderate interaction that could exacerbate diseases when taken with Danazol and Danazol (Compound) resembles Quines... |
DB06410 | DB09104 | 1,196 | 286 | [
"DDInter595",
"DDInter1118"
] | Doxercalciferol | Magnesium hydroxide | Doxercalciferol is a synthetic vitamin D2 analog that undergoes metabolic activation in vivo to form 1α,25-dihydroxyvitamin D2 (1α,25-(OH)2D2), a naturally occurring, biologically active form of vitamin D2. Doxercalciferol is indicated for the treatment of secondary hyperparathyroidism in patients with chronic kidney d... | Magnesium hydroxide is an inorganic compound. It is naturally found as the mineral brucite. Magnesium hydroxide can be used as an antacid or a laxative in either an oral liquid suspension or chewable tablet form. Additionally, magnesium hydroxide has smoke suppressing and flame retardant properties and is thus used com... | Moderate | 1 | [
[
[
1196,
24,
286
]
],
[
[
1196,
63,
1482
],
[
1482,
23,
286
]
],
[
[
1196,
63,
362
],
[
362,
24,
286
]
],
[
[
1196,
24,
1333
],
[
1333,
... | [
[
[
"Doxercalciferol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Magnesium hydroxide"
]
],
[
[
"Doxercalciferol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Digitoxi... | Doxercalciferol may cause a moderate interaction that could exacerbate diseases when taken with Digitoxin and Digitoxin may cause a minor interaction that can limit clinical effects when taken with Magnesium hydroxide
Doxercalciferol may cause a moderate interaction that could exacerbate diseases when taken with Phenyt... |
DB00561 | DB01037 | 1,048 | 1,161 | [
"DDInter591",
"DDInter1653"
] | Doxapram | Selegiline | A central respiratory stimulant with a brief duration of action. (From Martindale, The Extra Pharmocopoeia, 30th ed, p1225) | A selective, irreversible inhibitor of Type B monoamine oxidase. It is used in newly diagnosed patients with Parkinson's disease. It may slow progression of the clinical disease and delay the requirement for levodopa therapy. It also may be given with levodopa upon onset of disability. (From AMA Drug Evaluations Annual... | Major | 2 | [
[
[
1048,
25,
1161
]
],
[
[
1048,
25,
551
],
[
551,
1,
1161
]
],
[
[
1048,
24,
280
],
[
280,
40,
1161
]
],
[
[
1048,
21,
28722
],
[
28722,... | [
[
[
"Doxapram",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Selegiline"
]
],
[
[
"Doxapram",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Phenelzine"
],
[
"Phenelzine",
"{u} (Comp... | Doxapram may lead to a major life threatening interaction when taken with Phenelzine and Phenelzine (Compound) resembles Selegiline (Compound)
Doxapram may cause a moderate interaction that could exacerbate diseases when taken with Mephentermine and Mephentermine (Compound) resembles Selegiline (Compound)
Doxapram (Com... |
DB00005 | DB00188 | 1,057 | 168 | [
"DDInter687",
"DDInter222"
] | Etanercept | Bortezomib | Dimeric fusion protein consisting of the extracellular ligand-binding portion of the human 75 kilodalton (p75) tumor necrosis factor receptor (TNFR) linked to the Fc portion of human IgG1.[L14862,A216522] The Fc component of etanercept contains the CH2 domain, the CH3 domain and hinge region, but not the CH1 domain of ... | Bortezomib is a dipeptide boronic acid derivative and proteasome inhibitor used to treat multiple myeloma and mantle cell lymphoma. The 26S proteasome is a protein complex that degrades ubiquitinated proteins in the ubiquitin-proteasome pathway: reversible inhibition of the 26S proteasome, leading to cell cycle arrest ... | Major | 2 | [
[
[
1057,
25,
168
]
],
[
[
1057,
25,
1307
],
[
1307,
62,
168
]
],
[
[
1057,
24,
126
],
[
126,
62,
168
]
],
[
[
1057,
24,
1487
],
[
1487,
... | [
[
[
"Etanercept",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Bortezomib"
]
],
[
[
"Etanercept",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Melphalan"
],
[
"Melphalan",
"{u} may... | Etanercept may lead to a major life threatening interaction when taken with Melphalan and Melphalan may cause a minor interaction that can limit clinical effects when taken with Bortezomib
Etanercept may cause a moderate interaction that could exacerbate diseases when taken with Warfarin and Warfarin may cause a minor ... |
DB00877 | DB06643 | 629 | 1,136 | [
"DDInter1678",
"DDInter500"
] | Sirolimus | Denosumab | Sirolimus, also known as rapamycin, is a macrocyclic lactone antibiotic produced by bacteria _Streptomyces hygroscopicus_, which was isolated from the soil of the Vai Atari region of Rapa Nui (Easter Island). It was first isolated and identified as an antifungal agent with potent anticandida activity; however, after it... | Denosumab is a novel, fully human IgG2 monoclonal antibody specific to receptor activator of nuclear factor kappa-B ligand (RANKL), suppresses bone resorption via inhibiting RANK-mediated activation of osteoclasts. It is the first and currently the only RANKL inhibitor approved to prevent osteoclast-mediated bone loss.... | Moderate | 1 | [
[
[
629,
24,
1136
]
],
[
[
629,
24,
1213
],
[
1213,
24,
1136
]
],
[
[
629,
63,
1555
],
[
1555,
24,
1136
]
],
[
[
629,
25,
1377
],
[
1377,
... | [
[
[
"Sirolimus",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Denosumab"
]
],
[
[
"Sirolimus",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dasatinib"
],
[
... | Sirolimus may cause a moderate interaction that could exacerbate diseases when taken with Dasatinib and Dasatinib may cause a moderate interaction that could exacerbate diseases when taken with Denosumab
Sirolimus may cause a moderate interaction that could exacerbate diseases when taken with Oxaliplatin and Oxaliplati... |
DB14004 | DB14409 | 398 | 1,129 | [
"DDInter1806",
"DDInter867"
] | Tildrakizumab | Human adenovirus e serotype 4 strain cl-68578 antigen | Tildrakizumab is a high-affinity, humanized, IgG1 κ antibody targeting interleukin 23 p19 that shows promise in the evolution of treatment strategy in chronic plaque psoriasis. The Food and Drug Administration (FDA) approved ILUMYA (tildrakizumab-asmn) for the treatment of adults with moderate-to-severe plaque psoriasi... | Human adenovirus e serotype 4 strain cl-68578 antigen is a vaccine. | Moderate | 1 | [
[
[
398,
24,
1129
]
],
[
[
398,
64,
1057
],
[
1057,
24,
1129
]
],
[
[
398,
63,
1683
],
[
1683,
24,
1129
]
],
[
[
398,
25,
676
],
[
676,
... | [
[
[
"Tildrakizumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Human adenovirus e serotype 4 strain cl-68578 antigen"
]
],
[
[
"Tildrakizumab",
"{u} may lead to a major life threatening interaction when taken with {v}",
... | Tildrakizumab may lead to a major life threatening interaction when taken with Etanercept and Etanercept may cause a moderate interaction that could exacerbate diseases when taken with Human adenovirus e serotype 4 strain cl-68578 antigen
Tildrakizumab may cause a moderate interaction that could exacerbate diseases whe... |
DB00060 | DB09078 | 912 | 1,228 | [
"DDInter947",
"DDInter1036"
] | Interferon beta-1a | Lenvatinib | Human interferon beta (166 residues), glycosylated, MW=22.5kD. It is produced by mammalian cells (Chinese Hamster Ovary cells) into which the human interferon beta gene has been introduced. The amino acid sequence is identical to that of natural human interferon beta. | Lenvatinib is a receptor tyrosine kinase (RTK) inhibitor that inhibits the kinase activities of vascular endothelial growth factor (VEGF) receptors VEGFR1 (FLT1), VEGFR2 (KDR), and VEGFR3 (FLT4). Lenvatinib also inhibits other RTKs that have been implicated in pathogenic angiogenesis, tumor growth, and cancer progressi... | Moderate | 1 | [
[
[
912,
24,
1228
]
],
[
[
912,
24,
463
],
[
463,
23,
1228
]
],
[
[
912,
24,
609
],
[
609,
24,
1228
]
],
[
[
912,
24,
1412
],
[
1412,
... | [
[
[
"Interferon beta-1a",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lenvatinib"
]
],
[
[
"Interferon beta-1a",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rifampicin"... | Interferon beta-1a may cause a moderate interaction that could exacerbate diseases when taken with Rifampicin and Rifampicin may cause a minor interaction that can limit clinical effects when taken with Lenvatinib
Interferon beta-1a may cause a moderate interaction that could exacerbate diseases when taken with Clarith... |
DB00448 | DB01082 | 1,215 | 1,448 | [
"DDInter1022",
"DDInter1713"
] | Lansoprazole | Streptomycin | Lansoprazole marketed under the brand Prevacid, is a proton pump inhibitor (PPI) and is structurally classified as a substituted benzimidazole. It reduces gastric acid secretion by targeting gastric H,K-ATPase pumps and is thus effective at promoting healing in ulcerative diseases, and treating gastroesophageal reflux ... | Streptomycin, an antibiotic derived from _Streptomyces griseus_, was the first aminoglycoside to be discovered and used in practice in the 1940s.[A233325,A233390] Selman Waksman and eventually Albert Schatz were recognized with the Nobel Prize in Medicine for their discovery of streptomycin and its antibacterial activi... | Moderate | 1 | [
[
[
1215,
24,
1448
]
],
[
[
1215,
21,
29327
],
[
29327,
60,
1448
]
],
[
[
1215,
24,
361
],
[
361,
24,
1448
]
],
[
[
1215,
40,
660
],
[
660... | [
[
[
"Lansoprazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Streptomycin"
]
],
[
[
"Lansoprazole",
"{u} (Compound) causes {v} (Side Effect)",
"Renal failure"
],
[
"Renal failure",
"{u} (Side E... | Lansoprazole (Compound) causes Renal failure (Side Effect) and Renal failure (Side Effect) is caused by Streptomycin (Compound)
Lansoprazole may cause a moderate interaction that could exacerbate diseases when taken with Neomycin and Neomycin may cause a moderate interaction that could exacerbate diseases when taken wi... |
DB00843 | DB11718 | 479 | 927 | [
"DDInter583",
"DDInter640"
] | Donepezil | Encorafenib | In 2016, the global burden of dementia was estimated to be 43.8 million, demonstrating a significant increase from a global prevalence of 20.2 million in 1990. Donepezil, also known as Aricept, is a piperidine derivative acetylcholinesterase inhibitor used in the management of the dementia of Alzheimer's Disease, and i... | Encorafenib, also known as _BRAFTOVI_, is a kinase inhibitor. Encorafenib inhibits BRAF gene, which encodes for B-raf protein, which is a proto-oncogene involved in various genetic mutations. This protein plays a role in regulating the MAP kinase/ERK signaling pathway, which impacts cell division, differentiation, and ... | Moderate | 1 | [
[
[
479,
24,
927
]
],
[
[
479,
24,
112
],
[
112,
23,
927
]
],
[
[
479,
63,
1324
],
[
1324,
24,
927
]
],
[
[
479,
24,
1491
],
[
1491,
... | [
[
[
"Donepezil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Encorafenib"
]
],
[
[
"Donepezil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Metronidazole"
],
[
... | Donepezil may cause a moderate interaction that could exacerbate diseases when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Encorafenib
Donepezil may cause a moderate interaction that could exacerbate diseases when taken with Troglitazone and T... |
DB00305 | DB01101 | 377 | 60 | [
"DDInter1232",
"DDInter285"
] | Mitomycin | Capecitabine | Mitomycin is an antineoplastic antibiotic first isolated by Japanese microbiologists in the 1950s from cultures of _Streptomyces caespitosus_.[L12867,A193419] It is an alkylating agent that inhibits DNA synthesis (and, at higher concentrations, RNA and protein synthesis) by cross-linking the complementary strands of th... | Capecitabine is an orally-administered chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. Capecitabine is a prodrug, that is enzymatically converted to fluorouracil (antimetabolite) in the tumor, where it inhibits DNA synthesis and slows growth of tumor tissue. | Moderate | 1 | [
[
[
377,
24,
60
]
],
[
[
377,
5,
11616
],
[
11616,
44,
60
]
],
[
[
377,
7,
6952
],
[
6952,
46,
60
]
],
[
[
377,
21,
28701
],
[
28701,
... | [
[
[
"Mitomycin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Capecitabine"
]
],
[
[
"Mitomycin",
"{u} (Compound) treats {v} (Disease)",
"stomach cancer"
],
[
"stomach cancer",
"{u} (Disease) is tr... | Mitomycin (Compound) treats stomach cancer (Disease) and stomach cancer (Disease) is treated by Capecitabine (Compound)
Mitomycin (Compound) upregulates MCOLN1 (Gene) and MCOLN1 (Gene) is upregulated by Capecitabine (Compound)
Mitomycin (Compound) causes Discomfort (Side Effect) and Discomfort (Side Effect) is caused b... |
DB00539 | DB01159 | 11 | 419 | [
"DDInter1837",
"DDInter854"
] | Toremifene | Halothane | Toremifene is a selective estrogen receptor modulator (SERM) and a nonsteroidal antiestrogen used to treat estrogen receptor positive breast cancer. Like [tamoxifen], toremifene is part of the first-generation triphenylethylene derivative chemical class of SERMs. Toremifene possesses tissue-specific actions: it has est... | A nonflammable, halogenated, hydrocarbon anesthetic that provides relatively rapid induction with little or no excitement. Analgesia may not be adequate. nitrous oxide is often given concomitantly. Because halothane may not produce sufficient muscle relaxation, supplemental neuromuscular blocking agents may be required... | Major | 2 | [
[
[
11,
25,
419
]
],
[
[
11,
6,
8374
],
[
8374,
45,
419
]
],
[
[
11,
23,
112
],
[
112,
23,
419
]
],
[
[
11,
24,
629
],
[
629,
24,
... | [
[
[
"Toremifene",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Halothane"
]
],
[
[
"Toremifene",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
"Halothan... | Toremifene (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Halothane (Compound)
Toremifene may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Halothane
Toremifene may cau... |
DB01229 | DB04865 | 973 | 4 | [
"DDInter1378",
"DDInter1335"
] | Paclitaxel (protein-bound) | Omacetaxine mepesuccinate | Paclitaxel can cause developmental toxicity, female reproductive toxicity and male reproductive toxicity according to state or federal government labeling requirements. | Omacetaxine mepesuccinate (formerly known as HHT or Homoharringtonine), is a cephalotaxine ester and protein synthesis inhibitor with established clinical activity as a single agent in hematological malignancies. Omacetaxine mepesuccinate is synthesized from cephalotaxine, which is an extract from the leaves of the pla... | Moderate | 1 | [
[
[
973,
24,
4
]
],
[
[
973,
7,
13042
],
[
13042,
46,
4
]
],
[
[
973,
18,
10351
],
[
10351,
46,
4
]
],
[
[
973,
18,
10488
],
[
10488,
... | [
[
[
"Paclitaxel",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Omacetaxine mepesuccinate"
]
],
[
[
"Paclitaxel",
"{u} (Compound) upregulates {v} (Gene)",
"HIST1H2BK"
],
[
"HIST1H2BK",
"{u} (Gene) i... | Paclitaxel may cause a moderate interaction that could exacerbate diseases when taken with Omacetaxine mepesuccinate
Paclitaxel (Compound) upregulates HIST1H2BK (Gene) and HIST1H2BK (Gene) is upregulated by Omacetaxine mepesuccinate (Compound)
Paclitaxel (Compound) downregulates ATF6 (Gene) and ATF6 (Gene) is upregulat... |
DB01041 | DB01069 | 770 | 401 | [
"DDInter1789",
"DDInter1533"
] | Thalidomide | Promethazine | A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, thalidomide was withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of inflammatory disorders and cancers. Thalidomide displays immunosuppressive and anti-angiogenic activity through modulating ... | Promethazine, originally known as 3,277 R.P., is an N-dimethylaminopropyl derivative of [phenothiazine] that was developed in France in 1946. Promethazine antagonizes a variety of receptors, allowing it to be used for a number of indications including allergic reactions, pain, sedation, nausea, and vomiting.[A189907,A1... | Moderate | 1 | [
[
[
770,
24,
401
]
],
[
[
770,
63,
146
],
[
146,
24,
401
]
],
[
[
770,
24,
1264
],
[
1264,
63,
401
]
],
[
[
770,
6,
6017
],
[
6017,
... | [
[
[
"Thalidomide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Promethazine"
]
],
[
[
"Thalidomide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Propiomazine"
],
... | Thalidomide may cause a moderate interaction that could exacerbate diseases when taken with Propiomazine and Propiomazine may cause a moderate interaction that could exacerbate diseases when taken with Promethazine
Thalidomide may cause a moderate interaction that could exacerbate diseases when taken with Doxepin and D... |
DB00289 | DB00857 | 847 | 1,387 | [
"DDInter132",
"DDInter1768"
] | Atomoxetine | Terbinafine | Atomoxetine is a selective norepinephrine (NE) reuptake inhibitor used for the treatment of attention deficit hyperactivity disorder (ADHD). Also known as the marketed product Strattera, atomoxetine is used with other treatment modalities (psychological, educational, cognitive behaviour therapy, etc) to improve develop... | Terbinafine hydrochloride (Lamisil) is a synthetic allylamine antifungal.[L9065,L9068] It is highly lipophilic in nature and tends to accumulate in skin, nails, and fatty tissues. Like other allylamines, terbinafine inhibits ergosterol synthesis by inhibiting the fungal squalene monooxygenase (also called squalene epox... | Moderate | 1 | [
[
[
847,
24,
1387
]
],
[
[
847,
40,
1576
],
[
1576,
1,
1387
]
],
[
[
847,
6,
8374
],
[
8374,
45,
1387
]
],
[
[
847,
18,
1954
],
[
1954,
... | [
[
[
"Atomoxetine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Terbinafine"
]
],
[
[
"Atomoxetine",
"{u} (Compound) resembles {v} (Compound)",
"Propranolol"
],
[
"Propranolol",
"{u} (Compound) res... | Atomoxetine (Compound) resembles Propranolol (Compound) and Propranolol (Compound) resembles Terbinafine (Compound)
Atomoxetine (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Terbinafine (Compound)
Atomoxetine (Compound) downregulates COG2 (Gene) and COG2 (Gene) is downregulated by Terbinafine (Compound)
... |
DB00176 | DB01246 | 529 | 820 | [
"DDInter770",
"DDInter45"
] | Fluvoxamine | Alimemazine | Fluvoxamine is an antidepressant which functions pharmacologically as a selective serotonin reuptake inhibitor. Though it is in the same class as other SSRI drugs, it is most often used to treat obsessive-compulsive disorder. Fluvoxamine has been in use in clinical practice since 1983 and has a clinical trial database ... | A phenothiazine derivative that is used as an antipruritic. | Moderate | 1 | [
[
[
529,
24,
820
]
],
[
[
529,
24,
401
],
[
401,
24,
820
]
],
[
[
529,
24,
649
],
[
649,
1,
820
]
],
[
[
529,
6,
8374
],
[
8374,
45,... | [
[
[
"Fluvoxamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alimemazine"
]
],
[
[
"Fluvoxamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Promethazine"
],
... | Fluvoxamine may cause a moderate interaction that could exacerbate diseases when taken with Promethazine and Promethazine may cause a moderate interaction that could exacerbate diseases when taken with Alimemazine
Fluvoxamine may cause a moderate interaction that could exacerbate diseases when taken with Clofedanol and... |
DB00761 | DB00792 | 1,621 | 832 | [
"DDInter1497",
"DDInter1878"
] | Potassium chloride | Tripelennamine | A white crystal or crystalline powder used as an electrolyte replenisher, in the treatment of hypokalemia, in buffer solutions, and in fertilizers and explosives. The FDA withdrew its approval for the use of all solid oral dosage form drug products containing potassium chloride that supply 100 mg or more of potassium p... | A histamine H1 antagonist with low sedative action but frequent gastrointestinal irritation. It is used to treat asthma; HAY fever; urticaria; and rhinitis; and also in veterinary applications. Tripelennamine is administered by various routes, including topically. | Major | 2 | [
[
[
1621,
25,
832
]
],
[
[
1621,
25,
100
],
[
100,
63,
832
]
],
[
[
1621,
64,
508
],
[
508,
1,
832
]
],
[
[
1621,
64,
1594
],
[
1594,
... | [
[
[
"Potassium chloride",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Tripelennamine"
]
],
[
[
"Potassium chloride",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Brompheniramine"
],
[
"... | Potassium chloride may lead to a major life threatening interaction when taken with Brompheniramine and Brompheniramine may cause a moderate interaction that could exacerbate diseases when taken with Tripelennamine
Potassium chloride may lead to a major life threatening interaction when taken with Promazine and Promazi... |
DB00393 | DB14724 | 854 | 48 | [
"DDInter1295",
"DDInter634"
] | Nimodipine | Emapalumab | Nimodipine is a 1,4-dihydropyridine calcium channel blocker. It acts primarily on vascular smooth muscle cells by stabilizing voltage-gated L-type calcium channels in their inactive conformation. By inhibiting the influx of calcium in smooth muscle cells, nimodipine prevents calcium-dependent smooth muscle contraction ... | Emapalumab, also known as NI-0501, is a fully human monoclonal antibody that targets interferon gamma. Emapalumab development was sponsored by NovImmune SA, further developed by Sobi and FDA approved on November 20, 2018.[A38676, L4840] The approval of emapalumab was followed by the designation of orphan drug, priority... | Moderate | 1 | [
[
[
854,
24,
48
]
],
[
[
854,
1,
376
],
[
376,
24,
48
]
],
[
[
854,
1,
376
],
[
376,
40,
1428
],
[
1428,
24,
48
]
],
[
[
854,
1,
... | [
[
[
"Nimodipine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Emapalumab"
]
],
[
[
"Nimodipine",
"{u} (Compound) resembles {v} (Compound)",
"Amlodipine"
],
[
"Amlodipine",
"{u} may cause a moderat... | Nimodipine (Compound) resembles Amlodipine (Compound) and Amlodipine may cause a moderate interaction that could exacerbate diseases when taken with Emapalumab
Nimodipine (Compound) resembles Amlodipine (Compound) and Amlodipine (Compound) resembles Isradipine (Compound) and Isradipine may cause a moderate interaction ... |
DB00773 | DB01101 | 896 | 60 | [
"DDInter702",
"DDInter285"
] | Etoposide | Capecitabine | A semisynthetic derivative of podophyllotoxin that exhibits antitumor activity. Etoposide inhibits DNA synthesis by forming a complex with topoisomerase II and DNA. This complex induces breaks in double stranded DNA and prevents repair by topoisomerase II binding. Accumulated breaks in DNA prevent entry into the mitoti... | Capecitabine is an orally-administered chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. Capecitabine is a prodrug, that is enzymatically converted to fluorouracil (antimetabolite) in the tumor, where it inhibits DNA synthesis and slows growth of tumor tissue. | Moderate | 1 | [
[
[
896,
24,
60
]
],
[
[
896,
5,
11562
],
[
11562,
44,
60
]
],
[
[
896,
21,
28701
],
[
28701,
60,
60
]
],
[
[
896,
23,
872
],
[
872,
... | [
[
[
"Etoposide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Capecitabine"
]
],
[
[
"Etoposide",
"{u} (Compound) treats {v} (Disease)",
"prostate cancer"
],
[
"prostate cancer",
"{u} (Disease) is ... | Etoposide (Compound) treats prostate cancer (Disease) and prostate cancer (Disease) is treated by Capecitabine (Compound)
Etoposide (Compound) causes Discomfort (Side Effect) and Discomfort (Side Effect) is caused by Capecitabine (Compound)
Etoposide may cause a minor interaction that can limit clinical effects when ta... |
DB08881 | DB11979 | 868 | 1,320 | [
"DDInter1925",
"DDInter625"
] | Vemurafenib | Elagolix | Vemurafenib is a competitive kinase inhibitor with activity against BRAF kinase with mutations like V600E. It exerts its function by binding to the ATP-binding domain of the mutant BRAF. Vemurafenib was co-developed by Roche and Plexxikon and it obtained its FDA approval on August 17, 2011, under the company Hoffmann L... | Elagolix has been used in trials studying the basic science and treatment of Endometriosis, Folliculogenesis, Uterine Fibroids, Heavy Uterine Bleeding, and Heavy Menstrual Bleeding. As of 24 July 2018, however, the U.S. Food and Drug Administration (FDA) approved AbbVie's elagolix under the brand name Orilissa as the f... | Moderate | 1 | [
[
[
868,
24,
1320
]
],
[
[
868,
62,
168
],
[
168,
23,
1320
]
],
[
[
868,
23,
271
],
[
271,
23,
1320
]
],
[
[
868,
25,
1612
],
[
1612,
... | [
[
[
"Vemurafenib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Elagolix"
]
],
[
[
"Vemurafenib",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Bortezomib"
],
[
... | Vemurafenib may cause a minor interaction that can limit clinical effects when taken with Bortezomib and Bortezomib may cause a minor interaction that can limit clinical effects when taken with Elagolix
Vemurafenib may cause a minor interaction that can limit clinical effects when taken with Mirabegron and Mirabegron m... |
DB00683 | DB01041 | 1,382 | 770 | [
"DDInter1212",
"DDInter1789"
] | Midazolam | Thalidomide | Midazolam is a short-acting hypnotic-sedative drug with anxiolytic, muscle relaxant, anticonvulsant, sedative, hypnotic, and amnesic properties. It belongs to a class of drugs called _benzodiazepines_. This drug is unique from others in this class due to its rapid onset of effects and short duration of action. Midazola... | A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, thalidomide was withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of inflammatory disorders and cancers. Thalidomide displays immunosuppressive and anti-angiogenic activity through modulating ... | Moderate | 1 | [
[
[
1382,
24,
770
]
],
[
[
1382,
6,
6365
],
[
6365,
45,
770
]
],
[
[
1382,
21,
29177
],
[
29177,
60,
770
]
],
[
[
1382,
24,
609
],
[
609,
... | [
[
[
"Midazolam",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Thalidomide"
]
],
[
[
"Midazolam",
"{u} (Compound) binds {v} (Gene)",
"CYP2E1"
],
[
"CYP2E1",
"{u} (Gene) is bound by {v} (Compound)",
... | Midazolam (Compound) binds CYP2E1 (Gene) and CYP2E1 (Gene) is bound by Thalidomide (Compound)
Midazolam (Compound) causes Musculoskeletal stiffness (Side Effect) and Musculoskeletal stiffness (Side Effect) is caused by Thalidomide (Compound)
Midazolam may cause a moderate interaction that could exacerbate diseases when... |
DB00774 | DB00992 | 1,577 | 842 | [
"DDInter889",
"DDInter1182"
] | Hydroflumethiazide | Methyl aminolevulinate (topical) | A thiazide diuretic with actions and uses similar to those of hydrochlorothiazide. (From Martindale, The Extra Pharmacopoeia, 30th ed, p822) | Methyl 5-aminolevulinate is the methyl ester of 5-aminolevulinic acid. A prodrug, it is metabolised to protoporphyrin IX, a photosensitizer, and is used in the photodynamic treatment of non-melanoma skin cancer (including basal cell carcinoma). Topical application (often as the hydrochloride salt) results in an accumul... | Moderate | 1 | [
[
[
1577,
24,
842
]
],
[
[
1577,
21,
28787
],
[
28787,
60,
842
]
],
[
[
1577,
63,
1274
],
[
1274,
24,
842
]
],
[
[
1577,
24,
820
],
[
820,... | [
[
[
"Hydroflumethiazide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Methyl aminolevulinate"
]
],
[
[
"Hydroflumethiazide",
"{u} (Compound) causes {v} (Side Effect)",
"Dermatitis"
],
[
"Dermatitis",
... | Hydroflumethiazide may cause a moderate interaction that could exacerbate diseases when taken with Methyl aminolevulinate
Hydroflumethiazide (Compound) causes Dermatitis (Side Effect) and Dermatitis (Side Effect) is caused by Methyl aminolevulinate (Compound)
Hydroflumethiazide may cause a moderate interaction that cou... |
DB00927 | DB06209 | 1,559 | 256 | [
"DDInter712",
"DDInter1508"
] | Famotidine | Prasugrel | Famotidine is a competitive histamine-2 (H<sub>2</sub>) receptor antagonist that works to inhibit gastric acid secretion. It is commonly used in gastrointestinal conditions related to acid secretion, such as gastric ulcers and gastroesophageal reflux disease (GERD), in adults and children. Compared to other H<sub>2</su... | Prasugrel, a thienopyridine derivative, is a platelet activation and aggregation inhibitor structurally and pharmacologically related to clopidogrel and ticlopidine. Similar to clopidogrel, prasugrel is a prodrug that requires enzymatic transformation in the liver to its active metabolite, R-138727. R-138727 irreversib... | Minor | 0 | [
[
[
1559,
23,
256
]
],
[
[
1559,
6,
10215
],
[
10215,
45,
256
]
],
[
[
1559,
21,
28681
],
[
28681,
60,
256
]
],
[
[
1559,
24,
419
],
[
419... | [
[
[
"Famotidine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Prasugrel"
]
],
[
[
"Famotidine",
"{u} (Compound) binds {v} (Gene)",
"CYP2C19"
],
[
"CYP2C19",
"{u} (Gene) is bound by {v} (Compound)",
... | Famotidine (Compound) binds CYP2C19 (Gene) and CYP2C19 (Gene) is bound by Prasugrel (Compound)
Famotidine (Compound) causes Hypersensitivity (Side Effect) and Hypersensitivity (Side Effect) is caused by Prasugrel (Compound)
Famotidine may cause a moderate interaction that could exacerbate diseases when taken with Halot... |
DB12015 | DB13928 | 1,033 | 1,385 | [
"DDInter53",
"DDInter1660"
] | Alpelisib | Semaglutide | Alpelisib is a phosphatidylinositol 3-kinase (PI3K) inhibitor with potent antitumor activity. It works by selectively inhibiting class I PI3K p110α, which is the catalytic subunit of PI3K, a lipid kinase that plays a role in various biological processes, including proliferation, survival, differentiation, and metabolis... | Semaglutide is a glucagon-like peptide 1 (GLP-1) analog used to manage type 2 diabetes along with lifestyle changes, such as dietary restrictions and increased physical activity.[A31421,L8681] Other members of this drug class include [Exenatide] and [Liraglutide]. Semaglutide was developed by Novo Nordisk and approved ... | Moderate | 1 | [
[
[
1033,
24,
1385
]
],
[
[
1033,
24,
1476
],
[
1476,
24,
1385
]
],
[
[
1033,
63,
154
],
[
154,
24,
1385
]
],
[
[
1033,
24,
1654
],
[
1654... | [
[
[
"Alpelisib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Semaglutide"
]
],
[
[
"Alpelisib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Brigatinib"
],
[
... | Alpelisib may cause a moderate interaction that could exacerbate diseases when taken with Brigatinib and Brigatinib may cause a moderate interaction that could exacerbate diseases when taken with Semaglutide
Alpelisib may cause a moderate interaction that could exacerbate diseases when taken with Lurasidone and Lurasid... |
DB00010 | DB11827 | 1,649 | 433 | [
"DDInter1661",
"DDInter669"
] | Sermorelin | Ertugliflozin | Sermorelin acetate is the acetate salt of an amidated synthetic 29-amino acid peptide (GRF 1-29 NH 2 ) that corresponds to the amino-terminal segment of the naturally occurring human growth hormone-releasing hormone (GHRH or GRF) consisting of 44 amino acid residues | Ertugliflozin is a sodium-dependent glucose cotransporter-2 (SGLT2) inhibitor used to treat type II diabetes mellitus. It works to block glucose reabsorption from the glomerulus. Ertugliflozin was first approved by the FDA in December 2017.[A261951, L1132] It was also approved by the European Commission in March 2018. | Moderate | 1 | [
[
[
1649,
24,
433
]
],
[
[
1649,
24,
959
],
[
959,
24,
433
]
],
[
[
1649,
24,
959
],
[
959,
62,
1103
],
[
1103,
23,
433
]
],
[
[
1649,
... | [
[
[
"Sermorelin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ertugliflozin"
]
],
[
[
"Sermorelin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Glipizide"
],
[
... | Sermorelin may cause a moderate interaction that could exacerbate diseases when taken with Glipizide and Glipizide may cause a moderate interaction that could exacerbate diseases when taken with Ertugliflozin
Sermorelin may cause a moderate interaction that could exacerbate diseases when taken with Glipizide and Glipiz... |
DB00358 | DB01193 | 1,010 | 819 | [
"DDInter1140",
"DDInter12"
] | Mefloquine | Acebutolol | Malaria is a protozoan disease that places an enormous burden on human health in endemic areas around the world. The 2020 World Health Organization malaria report indicates a 60% decrease in the global malaria fatality rate between 2000 to 2019. Despite this, malaria remains a significant cause of morbidity and mortali... | A cardioselective beta-adrenergic antagonist with little effect on the bronchial receptors. The drug has stabilizing and quinidine-like effects on cardiac rhythm as well as weak inherent sympathomimetic action. | Moderate | 1 | [
[
[
1010,
24,
819
]
],
[
[
1010,
24,
887
],
[
887,
1,
819
]
],
[
[
1010,
63,
88
],
[
88,
1,
819
]
],
[
[
1010,
6,
12523
],
[
12523,
... | [
[
[
"Mefloquine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Acebutolol"
]
],
[
[
"Mefloquine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pindolol"
],
[
... | Mefloquine may cause a moderate interaction that could exacerbate diseases when taken with Pindolol and Pindolol (Compound) resembles Acebutolol (Compound)
Mefloquine may cause a moderate interaction that could exacerbate diseases when taken with Metoprolol and Metoprolol (Compound) resembles Acebutolol (Compound)
Mefl... |
DB12245 | DB12825 | 823 | 1,375 | [
"DDInter1863",
"DDInter1032"
] | Triclabendazole | Lefamulin | Triclabendazole, manufactured by Novartis pharmaceuticals, is an antihelminthic drug that was approved by the FDA in February 2019 for the treatment of fascioliasis in humans.[FDA label, L5452] Fascioliasis is a parasitic infection often caused by the helminth, _Fasciola hepatica_, which is also known as “the common li... | Lefamulin is a pleuromutilin antibiotic used for the treatment of bacterial community-acquired pneumonia. A pleuromotilin is a more recently developed type of antibiotic that is derived from the fungus, Pleurotus mutilus. Lefamulin is available in intravenous and oral preparations and was granted FDA approval in August... | Major | 2 | [
[
[
823,
25,
1375
]
],
[
[
823,
62,
112
],
[
112,
23,
1375
]
],
[
[
823,
63,
659
],
[
659,
24,
1375
]
],
[
[
823,
24,
1619
],
[
1619,
... | [
[
[
"Triclabendazole",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Lefamulin"
]
],
[
[
"Triclabendazole",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
[
"... | Triclabendazole may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Lefamulin
Triclabendazole may cause a moderate interaction that could exacerbate diseases when taken with Vilanterol... |
DB00776 | DB01229 | 1,335 | 973 | [
"DDInter1360",
"DDInter1378"
] | Oxcarbazepine | Paclitaxel (protein-bound) | Oxcarbazepine is an anti-epileptic medication used in the treatment of partial onset seizures that was first approved for use in the United States in 2000.[L8627,L8630,L8633] It is a structural derivative of [carbamazepine] and exerts a majority of its activity via a pharmacologically active metabolite, MHD, which exis... | Paclitaxel can cause developmental toxicity, female reproductive toxicity and male reproductive toxicity according to state or federal government labeling requirements. | Moderate | 1 | [
[
[
1335,
24,
973
]
],
[
[
1335,
24,
310
],
[
310,
63,
973
]
],
[
[
1335,
6,
7524
],
[
7524,
45,
973
]
],
[
[
1335,
21,
28779
],
[
28779,
... | [
[
[
"Oxcarbazepine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Paclitaxel"
]
],
[
[
"Oxcarbazepine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cabazitaxel"
],
... | Oxcarbazepine may cause a moderate interaction that could exacerbate diseases when taken with Paclitaxel
Oxcarbazepine may cause a moderate interaction that could exacerbate diseases when taken with Cabazitaxel and Cabazitaxel may cause a moderate interaction that could exacerbate diseases when taken with Paclitaxel
Ox... |
DB00374 | DB00524 | 1,061 | 811 | [
"DDInter1852",
"DDInter1199"
] | Treprostinil | Metolazone | Treprostinil is a stable tricyclic analogue of prostacyclin that promotes the vasodilation of pulmonary and systemic arterial vascular beds and the inhibition of platelet aggregation.[L41855,L41860,L41865] It reduces symptoms in patients with pulmonary arterial hypertension (PAH) and pulmonary hypertension associated w... | A quinazoline-sulfonamide that is considered a thiazide-like diuretic which is long-acting so useful in chronic renal failure. It also tends to lower blood pressure and increase potassium loss. | Moderate | 1 | [
[
[
1061,
24,
811
]
],
[
[
1061,
24,
1605
],
[
1605,
40,
811
]
],
[
[
1061,
24,
1014
],
[
1014,
1,
811
]
],
[
[
1061,
21,
28850
],
[
28850... | [
[
[
"Treprostinil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Metolazone"
]
],
[
[
"Treprostinil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Indapamide"
],
... | Treprostinil may cause a moderate interaction that could exacerbate diseases when taken with Indapamide and Indapamide (Compound) resembles Metolazone (Compound)
Treprostinil may cause a moderate interaction that could exacerbate diseases when taken with Benzthiazide and Benzthiazide (Compound) resembles Metolazone (Co... |
DB08875 | DB08918 | 1,618 | 41 | [
"DDInter262",
"DDInter1059"
] | Cabozantinib | Levomilnacipran | Cabozantinib was first approved in 2012 and is a non-specific tyrosine kinase inhibitor. It was initially approved in the US under the brand name Cometriq, which is indicated for the treatment of metastatic medullary thyroid cancer. In 2016, a capsule formulation (Cabometyx) was approved for the treatment of advanced r... | Levomilnacipran is a selective serotonin and norepinephrine reuptake inhibitor (SNRI), although it is a more potent inhibitor of norepinephrine reuptake than serotonin reuptake.[A261181, A38560] Levomilnacipran is the more active 1S,2R-enantiomer in the racemate [milnacipran].[A261181, L47956] Once administered, interc... | Moderate | 1 | [
[
[
1618,
24,
41
]
],
[
[
1618,
63,
901
],
[
901,
40,
41
]
],
[
[
1618,
25,
498
],
[
498,
63,
41
]
],
[
[
1618,
64,
330
],
[
330,
24... | [
[
[
"Cabozantinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Levomilnacipran"
]
],
[
[
"Cabozantinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Milnacipran"
]... | Cabozantinib may cause a moderate interaction that could exacerbate diseases when taken with Milnacipran and Milnacipran (Compound) resembles Levomilnacipran (Compound)
Cabozantinib may lead to a major life threatening interaction when taken with Edoxaban and Edoxaban may cause a moderate interaction that could exacerb... |
DB00501 | DB11581 | 752 | 1,456 | [
"DDInter380",
"DDInter1926"
] | Cimetidine | Venetoclax | A histamine congener, it competitively inhibits histamine binding to histamine H2 receptors. Cimetidine has a range of pharmacological actions. It inhibits gastric acid secretion, as well as pepsin and gastrins output. It also blocks the activity of cytochrome P-450 which might explain proposals for use in neoadjuvant ... | Venetoclax is a BCL-2 inhibitor that was initially approved by the FDA in April 2016 [FDA label]. Proteins in the B cell CLL/lymphoma 2 (BCL-2) family are important regulators of the apoptotic (programmed cell death) process , . Venetoclax is used to treat chronic lymphocytic leukemia (CLL) and certain types of small l... | Moderate | 1 | [
[
[
752,
24,
1456
]
],
[
[
752,
23,
1135
],
[
1135,
23,
1456
]
],
[
[
752,
62,
536
],
[
536,
24,
1456
]
],
[
[
752,
24,
1476
],
[
1476,
... | [
[
[
"Cimetidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Venetoclax"
]
],
[
[
"Cimetidine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Naloxegol"
],
[
... | Cimetidine may cause a minor interaction that can limit clinical effects when taken with Naloxegol and Naloxegol may cause a minor interaction that can limit clinical effects when taken with Venetoclax
Cimetidine may cause a minor interaction that can limit clinical effects when taken with Secobarbital and Secobarbital... |
DB00163 | DB09312 | 1,461 | 967 | [
"DDInter1943",
"DDInter103"
] | Vitamin E | Antilymphocyte immunoglobulin (horse) | In 1922, vitamin E was demonstrated to be an essential nutrient. Vitamin E is a term used to describe 8 different fat soluble tocopherols and tocotrienols, alpha-tocopherol being the most biologically active. Vitamin E acts as an antioxidant, protecting cell membranes from oxidative damage. The antioxidant effects are ... | Equine anti-thymocyte globulin is composed of purified gamma globulin containing primarily IgG against human thymus lymphocytes. It is formed by inoculating a horse with an antigen (human thymoyctes) which then induces the horse immune system's B-lymphocytes to produce IgG immunoglobulins specific for that antigen. The... | Minor | 0 | [
[
[
1461,
62,
967
]
],
[
[
1461,
23,
1683
],
[
1683,
24,
967
]
],
[
[
1461,
23,
1531
],
[
1531,
63,
967
]
],
[
[
1461,
62,
66
],
[
66,
... | [
[
[
"Vitamin E",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Antilymphocyte immunoglobulin (horse)"
]
],
[
[
"Vitamin E",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Usteki... | Vitamin E may cause a minor interaction that can limit clinical effects when taken with Ustekinumab and Ustekinumab may cause a moderate interaction that could exacerbate diseases when taken with Antilymphocyte immunoglobulin (horse)
Vitamin E may cause a minor interaction that can limit clinical effects when taken wit... |
DB01015 | DB08871 | 1,247 | 36 | [
"DDInter1724",
"DDInter666"
] | Sulfamethoxazole | Eribulin | Sulfamethoxazole is a bacteriostatic sulfonamide antibiotic that interferes with folic acid synthesis in susceptible bacteria. It is generally given in combination with [trimethoprim], which inhibits a sequential step in bacterial folic acid synthesis - these agents work synergistically to block two consecutive steps i... | Eribulin is a microtubule inhibitor indicated for the treatment of patients with metastatic breast cancer who have previously received at least two chemotherapeutic regimens for the treatment of metastatic disease. Eribulin was isolated from the marine sponge Halichondria okadai. Eribulin is also being investigated for... | Minor | 0 | [
[
[
1247,
23,
36
]
],
[
[
1247,
62,
1424
],
[
1424,
24,
36
]
],
[
[
1247,
23,
820
],
[
820,
24,
36
]
],
[
[
1247,
24,
384
],
[
384,
... | [
[
[
"Sulfamethoxazole",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Eribulin"
]
],
[
[
"Sulfamethoxazole",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Quinine"
],
[... | Sulfamethoxazole may cause a minor interaction that can limit clinical effects when taken with Quinine and Quinine may cause a moderate interaction that could exacerbate diseases when taken with Eribulin
Sulfamethoxazole may cause a minor interaction that can limit clinical effects when taken with Alimemazine and Alime... |
DB00432 | DB10429 | 1,083 | 200 | [
"DDInter1868",
"DDInter282"
] | Trifluridine | Candida albicans | Trifluridine is a fluorinated pyrimidine nucleoside that is structurally related to [idoxuridine]. It is an active antiviral agent in ophthalmic solutions used mainly in the treatment of primary keratoconjunctivitis and recurrent epithelial keratitis due to herpes simplex virus. It displays effective antiviral activity... | Candida albicans is a fungus which can provoke allergic reactions. Candida albicans is used in allergenic testing. | Moderate | 1 | [
[
[
1083,
24,
200
]
],
[
[
1083,
24,
1683
],
[
1683,
24,
200
]
],
[
[
1083,
25,
976
],
[
976,
24,
200
]
],
[
[
1083,
40,
141
],
[
141,
... | [
[
[
"Trifluridine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Candida albicans"
]
],
[
[
"Trifluridine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ustekinumab"
... | Trifluridine may cause a moderate interaction that could exacerbate diseases when taken with Ustekinumab and Ustekinumab may cause a moderate interaction that could exacerbate diseases when taken with Candida albicans
Trifluridine may lead to a major life threatening interaction when taken with Tofacitinib and Tofaciti... |
DB00445 | DB11837 | 322 | 1,297 | [
"DDInter655",
"DDInter1351"
] | Epirubicin | Osilodrostat | An anthracycline which is the 4'-epi-isomer of doxorubicin. The compound exerts its antitumor effects by interference with the synthesis and function of DNA. | Osilodrostat is an inhibitor of 11β-hydroxylase (also referred to as CYP11B1), the enzyme that catalyzes the final step in the biosynthesis of endogenous cortisol. It is used to lower circulating cortisol levels in the treatment of Cushing's disease, a disorder in which cortisol levels are chronically and supraphysiolo... | Moderate | 1 | [
[
[
322,
24,
1297
]
],
[
[
322,
23,
112
],
[
112,
23,
1297
]
],
[
[
322,
24,
1320
],
[
1320,
63,
1297
]
],
[
[
322,
24,
623
],
[
623,
... | [
[
[
"Epirubicin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Osilodrostat"
]
],
[
[
"Epirubicin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
[... | Epirubicin may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Osilodrostat
Epirubicin may cause a moderate interaction that could exacerbate diseases when taken with Elagolix and Elag... |
DB00421 | DB01177 | 443 | 77 | [
"DDInter1707",
"DDInter904"
] | Spironolactone | Idarubicin | Spironolactone is a potassium-sparing diuretic. It binds to mineralocorticoid receptors and functions as aldosterone antagonists. It promotes sodium and water excretion and potassium retention. Spironolactone was originally developed purely for this ability before other pharmacodynamic properties of the drug were disco... | An orally administered anthracycline antineoplastic. The compound has shown activity against breast cancer, lymphomas and leukemias, together with the potential for reduced cardiac toxicity. | Moderate | 1 | [
[
[
443,
24,
77
]
],
[
[
443,
7,
9489
],
[
9489,
46,
77
]
],
[
[
443,
18,
1870
],
[
1870,
57,
77
]
],
[
[
443,
21,
28787
],
[
28787,
... | [
[
[
"Spironolactone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Idarubicin"
]
],
[
[
"Spironolactone",
"{u} (Compound) upregulates {v} (Gene)",
"WIF1"
],
[
"WIF1",
"{u} (Gene) is upregulated by ... | Spironolactone (Compound) upregulates WIF1 (Gene) and WIF1 (Gene) is upregulated by Idarubicin (Compound)
Spironolactone (Compound) downregulates MYC (Gene) and MYC (Gene) is downregulated by Idarubicin (Compound)
Spironolactone (Compound) causes Dermatitis (Side Effect) and Dermatitis (Side Effect) is caused by Idarub... |
DB00191 | DB00543 | 73 | 87 | [
"DDInter1447",
"DDInter82"
] | Phentermine | Amoxapine | Phentermine is a sympathomimetic amine anorectic agent and it was introduced in 1959 as part of an anti-obesity combination drug.[A174361, A174364] It is chemically related to amphetamine and it is commonly referred to as an atypical amphetamine. Phentermine has not been reported an addictive potential which allows thi... | Amoxapine, the <i>N</i>-demethylated derivative of the antipsychotic agent loxapine, is a dibenzoxazepine-derivative tricyclic antidepressant (TCA). TCAs are structurally similar to phenothiazines. They contain a tricyclic ring system with an alkyl amine substituent on the central ring. In non-depressed individuals, am... | Moderate | 1 | [
[
[
73,
24,
87
]
],
[
[
73,
6,
12523
],
[
12523,
45,
87
]
],
[
[
73,
21,
29232
],
[
29232,
60,
87
]
],
[
[
73,
24,
959
],
[
959,
63,... | [
[
[
"Phentermine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Amoxapine"
]
],
[
[
"Phentermine",
"{u} (Compound) binds {v} (Gene)",
"CYP2D6"
],
[
"CYP2D6",
"{u} (Gene) is bound by {v} (Compound)"... | Phentermine (Compound) binds CYP2D6 (Gene) and CYP2D6 (Gene) is bound by Amoxapine (Compound)
Phentermine (Compound) causes Urticaria (Side Effect) and Urticaria (Side Effect) is caused by Amoxapine (Compound)
Phentermine may cause a moderate interaction that could exacerbate diseases when taken with Glipizide and Glip... |
DB00443 | DB00728 | 251 | 1,610 | [
"DDInter195",
"DDInter1612"
] | Betamethasone | Rocuronium | Betamethasone is a long-acting corticosteroid with immunosuppressive and antiinflammatory properties. It can be used topically to manage inflammatory skin conditions such as eczema, and parenterally to manage several disease states including autoimmune disorders. Betamethasone has potent glucocorticoid activity and neg... | Rocuronium (rapid onset-curonium) is a desacetoxy analogue of vecuronium with a more rapid onset of action. It is an aminosteroid non-depolarizing neuromuscular blocker or muscle relaxant used in modern anaesthesia, to facilitate endotracheal intubation and to provide skeletal muscle relaxation during surgery or mechan... | Moderate | 1 | [
[
[
251,
24,
1610
]
],
[
[
251,
24,
728
],
[
728,
40,
1610
]
],
[
[
251,
21,
28778
],
[
28778,
60,
1610
]
],
[
[
251,
40,
167
],
[
167,
... | [
[
[
"Betamethasone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rocuronium"
]
],
[
[
"Betamethasone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vecuronium"
],
... | Betamethasone may cause a moderate interaction that could exacerbate diseases when taken with Vecuronium and Vecuronium (Compound) resembles Rocuronium (Compound)
Betamethasone (Compound) causes Anaphylactic shock (Side Effect) and Anaphylactic shock (Side Effect) is caused by Rocuronium (Compound)
Betamethasone (Compo... |
DB00459 | DB00855 | 640 | 213 | [
"DDInter21",
"DDInter72"
] | Acitretin | Aminolevulinic acid | An oral retinoid effective in the treatment of psoriasis. It is the major metabolite of etretinate with the advantage of a much shorter half-life when compared with etretinate. | A compound produced from succinyl-CoA and glycine as an intermediate in heme synthesis. It is used as a photochemotherapy for actinic keratosis. [PubChem] | Major | 2 | [
[
[
640,
25,
213
]
],
[
[
640,
21,
28880
],
[
28880,
60,
213
]
],
[
[
640,
25,
1572
],
[
1572,
25,
213
]
],
[
[
640,
63,
245
],
[
245,
... | [
[
[
"Acitretin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Aminolevulinic acid"
]
],
[
[
"Acitretin",
"{u} (Compound) causes {v} (Side Effect)",
"Angiopathy"
],
[
"Angiopathy",
"{u} (Side Effect) is caused by ... | Acitretin (Compound) causes Angiopathy (Side Effect) and Angiopathy (Side Effect) is caused by Aminolevulinic acid (Compound)
Acitretin may lead to a major life threatening interaction when taken with Demeclocycline and Demeclocycline may lead to a major life threatening interaction when taken with Aminolevulinic acid
... |
DB00191 | DB00816 | 73 | 1,674 | [
"DDInter1447",
"DDInter1346"
] | Phentermine | Orciprenaline | Phentermine is a sympathomimetic amine anorectic agent and it was introduced in 1959 as part of an anti-obesity combination drug.[A174361, A174364] It is chemically related to amphetamine and it is commonly referred to as an atypical amphetamine. Phentermine has not been reported an addictive potential which allows thi... | A beta-adrenergic agonist used in the treatment of asthma and bronchospasms. [PubChem] | Moderate | 1 | [
[
[
73,
24,
1674
]
],
[
[
73,
24,
874
],
[
874,
24,
1674
]
],
[
[
73,
21,
28921
],
[
28921,
60,
1674
]
],
[
[
73,
63,
1685
],
[
1685,
... | [
[
[
"Phentermine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Orciprenaline"
]
],
[
[
"Phentermine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Epinephrine"
],
... | Phentermine may cause a moderate interaction that could exacerbate diseases when taken with Epinephrine and Epinephrine may cause a moderate interaction that could exacerbate diseases when taken with Orciprenaline
Phentermine (Compound) causes Dizziness (Side Effect) and Dizziness (Side Effect) is caused by Orciprenali... |
DB01001 | DB06655 | 688 | 5 | [
"DDInter1632",
"DDInter1077"
] | Salbutamol | Liraglutide | Salbutamol is a short-acting, selective beta2-adrenergic receptor agonist used in the treatment of asthma and COPD. It is 29 times more selective for beta2 receptors than beta1 receptors giving it higher specificity for pulmonary beta receptors versus beta1-adrenergic receptors located in the heart. Salbutamol is formu... | Victoza contains liraglutide, a synthetic analog of human glucagon-like peptide-1(GLP-1) and acts as a GLP-1 receptor agonist.[Label,A6932] Liraglutide is 97% similar to native human GLP-1, differing primarily by substituting arginine for lysine at position 34. Liraglutide is made by attaching a C-16 fatty acid (palmit... | Moderate | 1 | [
[
[
688,
24,
5
]
],
[
[
688,
63,
1252
],
[
1252,
23,
5
]
],
[
[
688,
62,
870
],
[
870,
24,
5
]
],
[
[
688,
63,
245
],
[
245,
24,
... | [
[
[
"Salbutamol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Liraglutide"
]
],
[
[
"Salbutamol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Digoxin"
],
[
... | Salbutamol may cause a moderate interaction that could exacerbate diseases when taken with Digoxin and Digoxin may cause a minor interaction that can limit clinical effects when taken with Liraglutide
Salbutamol may cause a minor interaction that can limit clinical effects when taken with Fludrocortisone and Fludrocort... |
DB00470 | DB04953 | 530 | 495 | [
"DDInter601",
"DDInter708"
] | Dronabinol | Ezogabine | Dronabinol (marketed as Marinol) is a synthetic form of delta-9-tetrahydrocannabinol (Δ⁹-THC), the primary psychoactive component of cannabis (marijuana). THC demonstrates its effects through weak partial agonist activity at Cannabinoid-1 (CB1R) and Cannabinoid-2 (CB2R) receptors, which results in the well-known effect... | Ezogabine (D23129) is a close structural analog of the centrally acting analgesic flupitrine. It is a neuronal potassium channel opener being developed as a first-in-class antiepileptic drug (AED) and is currently being studied in Phase 3 trials as an adjunctive treatment for partial-onset seizures in adult patients wi... | Moderate | 1 | [
[
[
530,
24,
495
]
],
[
[
530,
6,
8717
],
[
8717,
45,
495
]
],
[
[
530,
21,
28997
],
[
28997,
60,
495
]
],
[
[
530,
24,
662
],
[
662,
... | [
[
[
"Dronabinol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ezogabine"
]
],
[
[
"Dronabinol",
"{u} (Compound) binds {v} (Gene)",
"CYP2A6"
],
[
"CYP2A6",
"{u} (Gene) is bound by {v} (Compound)",
... | Dronabinol (Compound) binds CYP2A6 (Gene) and CYP2A6 (Gene) is bound by Ezogabine (Compound)
Dronabinol (Compound) causes Ill-defined disorder (Side Effect) and Ill-defined disorder (Side Effect) is caused by Ezogabine (Compound)
Dronabinol may cause a moderate interaction that could exacerbate diseases when taken with... |
DB00377 | DB00845 | 1,494 | 1,490 | [
"DDInter1382",
"DDInter406"
] | Palonosetron | Clofazimine | Palonosetron (INN, trade name Aloxi) is an antagonist of 5-HT3 receptors that is indicated for the prevention and treatment of chemotherapy-induced nausea and vomiting (CINV). It is the most effective of the 5-HT3 antagonists in controlling delayed CINV nausea and vomiting that appear more than 24 hours after the first... | Clofazimine is a highly lipophilic antimicrobial riminophenazine dye used in combination with other agents, such as [dapsone], for the treatment of leprosy. It was originally described in 1957 and was the prototypical riminophenazine dye - a bright-red dye that, in its clinical use, results in long-lasting discoloratio... | Moderate | 1 | [
[
[
1494,
24,
1490
]
],
[
[
1494,
6,
8374
],
[
8374,
45,
1490
]
],
[
[
1494,
21,
28787
],
[
28787,
60,
1490
]
],
[
[
1494,
23,
112
],
[
11... | [
[
[
"Palonosetron",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clofazimine"
]
],
[
[
"Palonosetron",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compou... | Palonosetron (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Clofazimine (Compound)
Palonosetron (Compound) causes Dermatitis (Side Effect) and Dermatitis (Side Effect) is caused by Clofazimine (Compound)
Palonosetron may cause a minor interaction that can limit clinical effects when taken with Metronidazo... |
DB00067 | DB06603 | 317 | 39 | [
"DDInter1921",
"DDInter1387"
] | Vasopressin | Panobinostat | Vasopressin (arginine-vasopressin or antidiuretic hormone) is a nonapeptide primarily produced in the hypothalamus that exhibits diverse physiological functions related to diuresis, hemodynamic modulation, and behaviour.[A110, A111, A112, A113, A228008] Vasopressin is very similar to oxytocin, differing in the third an... | Panobinostat is an oral deacetylace (DAC) inhibitor approved on February 23, 2015 by the FDA for the treatment of multiple myeloma. The approval was accelerated based on progression-free survival, therefore confirmatory trials by the sponsor to demonstrate clinical efficacy in multiple myeloma treatment are in progress... | Major | 2 | [
[
[
317,
25,
39
]
],
[
[
317,
23,
112
],
[
112,
23,
39
]
],
[
[
317,
24,
455
],
[
455,
24,
39
]
],
[
[
317,
24,
144
],
[
144,
63,
... | [
[
[
"Vasopressin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Panobinostat"
]
],
[
[
"Vasopressin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
[
"Metro... | Vasopressin may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Panobinostat
Vasopressin may cause a moderate interaction that could exacerbate diseases when taken with Salmeterol and ... |
DB00673 | DB15093 | 723 | 1,654 | [
"DDInter112",
"DDInter1698"
] | Aprepitant | Somapacitan | Aprepitant, an antiemetic, is a substance P/neurokinin 1 (NK1) receptor antagonist which, in combination with other antiemetic agents, is indicated for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy. Aprepitant is a selective h... | Somapacitan, also known as NNC0195-0092, is a growth hormone analog indicated to treat adults with growth hormone deficiency.[A219126,L15661] This human growth hormone analog differs by the creation of an albumin binding site, and prolonging the effect so that it requires weekly dosing rather than daily. Somapacitan wa... | Moderate | 1 | [
[
[
723,
24,
1654
]
],
[
[
723,
63,
608
],
[
608,
23,
1654
]
],
[
[
723,
63,
10
],
[
10,
24,
1654
]
],
[
[
723,
25,
1135
],
[
1135,
... | [
[
[
"Aprepitant",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Somapacitan"
]
],
[
[
"Aprepitant",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lidocaine"
],
[
... | Aprepitant may cause a moderate interaction that could exacerbate diseases when taken with Lidocaine and Lidocaine may cause a minor interaction that can limit clinical effects when taken with Somapacitan
Aprepitant may cause a moderate interaction that could exacerbate diseases when taken with Dapsone and Dapsone may ... |
DB01041 | DB15965 | 770 | 1,330 | [
"DDInter1789",
"DDInter1270"
] | Thalidomide | Naxitamab | A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, thalidomide was withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of inflammatory disorders and cancers. Thalidomide displays immunosuppressive and anti-angiogenic activity through modulating ... | Naxitamab (humanized 3F8, hu3F8) is an IgG1 monoclonal antibody directed against the oncofetal differentiation antigen GD2 disialoganglioside.[L24454,A224604] Normally expressed during fetal development and in mature neurons, pain fibers, and skin cells, GD2 constitutes a highly efficient target in the treatment of neu... | Moderate | 1 | [
[
[
770,
24,
1330
]
],
[
[
770,
25,
1532
],
[
1532,
24,
1330
]
],
[
[
770,
24,
14
],
[
14,
24,
1330
]
],
[
[
770,
63,
10
],
[
10,
24... | [
[
[
"Thalidomide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Naxitamab"
]
],
[
[
"Thalidomide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ifosfamide"
],
[
"Ifosfamid... | Thalidomide may lead to a major life threatening interaction when taken with Ifosfamide and Ifosfamide may cause a moderate interaction that could exacerbate diseases when taken with Naxitamab
Thalidomide may cause a moderate interaction that could exacerbate diseases when taken with Rosuvastatin and Rosuvastatin may c... |
DB08870 | DB11817 | 850 | 1,259 | [
"DDInter228",
"DDInter165"
] | Brentuximab vedotin | Baricitinib | Brentuximab vedotin, also known as Adcetris®, is an antibody-drug conjugate that combines an anti-CD30 antibody with the drug monomethyl auristatin E (MMAE). It is an anti-neoplastic agent used in the treatment of Hodgkin's lymphoma and systemic anaplastic large-cell lymphoma. Brentuximab vedotin was initially approved... | Baricitinib is a Janus kinase (JAK) inhibitor. JAKs are tyrosine protein kinases that play an important role in pro-inflammatory signaling pathways. Overactive JAKs have been implicated in autoimmune disorders, such as rheumatoid arthritis. By inhibiting the actions of JAK1 and JAK2, baricitinib attenuates JAK-mediated... | Major | 2 | [
[
[
850,
25,
1259
]
],
[
[
850,
63,
1274
],
[
1274,
24,
1259
]
],
[
[
850,
24,
949
],
[
949,
24,
1259
]
],
[
[
850,
24,
1129
],
[
1129,
... | [
[
[
"Brentuximab vedotin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Baricitinib"
]
],
[
[
"Brentuximab vedotin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Flurbiprofen"
],
... | Brentuximab vedotin may cause a moderate interaction that could exacerbate diseases when taken with Flurbiprofen and Flurbiprofen may cause a moderate interaction that could exacerbate diseases when taken with Baricitinib
Brentuximab vedotin may cause a moderate interaction that could exacerbate diseases when taken wit... |
DB00687 | DB01009 | 870 | 935 | [
"DDInter747",
"DDInter1009"
] | Fludrocortisone | Ketoprofen | Fludrocortisone is a synthetic mineralocorticoid used in conjunction with [hydrocortisone] to replace missing endogenous corticosteroids in patients with adrenal insufficiency.[A187169,A187187] It is functionally similar to [aldosterone], the body's primary endogenous mineralocorticoid, and is structurally analogous to... | Ketoprofen, a propionic acid derivative, is a nonsteroidal anti-inflammatory agent (NSAIA) with analgesic and antipyretic properties. | Moderate | 1 | [
[
[
870,
24,
935
]
],
[
[
870,
63,
1523
],
[
1523,
40,
935
]
],
[
[
870,
24,
1274
],
[
1274,
24,
935
]
],
[
[
870,
24,
1263
],
[
1263,
... | [
[
[
"Fludrocortisone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ketoprofen"
]
],
[
[
"Fludrocortisone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Labetalol"
],... | Fludrocortisone may cause a moderate interaction that could exacerbate diseases when taken with Labetalol and Labetalol (Compound) resembles Ketoprofen (Compound)
Fludrocortisone may cause a moderate interaction that could exacerbate diseases when taken with Flurbiprofen and Flurbiprofen may cause a moderate interactio... |
DB00081 | DB01097 | 273 | 1,377 | [
"DDInter1838",
"DDInter1033"
] | Tositumomab | Leflunomide | Murine IgG2a lambda monoclonal antibody against CD20 antigen (2 heavy chains of 451 residues, 2 lambda chains of 220 residues). It is produced in an antibiotic-free culture of mammalian cells. It can be covalently linked to Iodine 131 (a radioactive isotope of iodine). | Leflunomide is a pyrimidine synthesis inhibitor belonging to the DMARD (disease-modifying antirheumatic drug) class of drugs, which are chemically and pharmacologically very heterogeneous. Leflunomide was approved by FDA and in many other countries (e.g., Canada, Europe) in 1999. | Major | 2 | [
[
[
273,
25,
1377
]
],
[
[
273,
24,
949
],
[
949,
63,
1377
]
],
[
[
273,
25,
126
],
[
126,
24,
1377
]
],
[
[
273,
24,
563
],
[
563,
... | [
[
[
"Tositumomab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Leflunomide"
]
],
[
[
"Tositumomab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clostridium tetani toxoid antigen (form... | Tositumomab may cause a moderate interaction that could exacerbate diseases when taken with Clostridium tetani toxoid antigen (formaldehyde inactivated) and Clostridium tetani toxoid antigen (formaldehyde inactivated) may cause a moderate interaction that could exacerbate diseases when taken with Leflunomide
Tositumoma... |
DB00601 | DB01098 | 453 | 14 | [
"DDInter1073",
"DDInter1622"
] | Linezolid | Rosuvastatin | Linezolid is a synthetic antibiotic which is used for the treatment of infections caused by aerobic Gram-positive bacteria. Its effects are bacteriostatic against both enterococci and staphylococci and bactericidal against most isolates of streptococci. Linezolid exerts its antibacterial activity by inhibiting the init... | Rosuvastatin, also known as the brand name product Crestor, is a lipid-lowering drug that belongs to the statin class of medications, which are used to lower the risk of cardiovascular disease and manage elevated lipid levels by inhibiting the endogenous production of cholesterol in the liver. More specifically, statin... | Moderate | 1 | [
[
[
453,
24,
14
]
],
[
[
453,
7,
3163
],
[
3163,
46,
14
]
],
[
[
453,
7,
2900
],
[
2900,
57,
14
]
],
[
[
453,
18,
7095
],
[
7095,
57... | [
[
[
"Linezolid",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rosuvastatin"
]
],
[
[
"Linezolid",
"{u} (Compound) upregulates {v} (Gene)",
"TSC22D3"
],
[
"TSC22D3",
"{u} (Gene) is upregulated by {v... | Linezolid (Compound) upregulates TSC22D3 (Gene) and TSC22D3 (Gene) is upregulated by Rosuvastatin (Compound)
Linezolid (Compound) upregulates NFKBIA (Gene) and NFKBIA (Gene) is downregulated by Rosuvastatin (Compound)
Linezolid (Compound) downregulates CCL2 (Gene) and CCL2 (Gene) is downregulated by Rosuvastatin (Compo... |
DB00104 | DB00661 | 966 | 122 | [
"DDInter1323",
"DDInter1928"
] | Octreotide | Verapamil | Acromegaly is a disorder caused by excess growth hormone (GH), increasing the growth of body tissues and causing metabolic dysfunction. In most cases, it results from an anterior pituitary growth hormone-releasing tumor. Typically, the feet, hands, and face grow abnormally large; organomegaly and insulin resistance may... | Verapamil is a phenylalkylamine calcium channel blocker used in the treatment of high blood pressure, heart arrhythmias, and angina, and was the first calcium channel antagonist to be introduced into therapy in the early 1960s. It is a member of the non-dihydropyridine class of calcium channel blockers, which includes ... | Moderate | 1 | [
[
[
966,
24,
122
]
],
[
[
966,
21,
28809
],
[
28809,
60,
122
]
],
[
[
966,
25,
1101
],
[
1101,
23,
122
]
],
[
[
966,
23,
466
],
[
466,
... | [
[
[
"Octreotide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Verapamil"
]
],
[
[
"Octreotide",
"{u} (Compound) causes {v} (Side Effect)",
"Diarrhoea"
],
[
"Diarrhoea",
"{u} (Side Effect) is cause... | Octreotide (Compound) causes Diarrhoea (Side Effect) and Diarrhoea (Side Effect) is caused by Verapamil (Compound)
Octreotide may lead to a major life threatening interaction when taken with Bexarotene and Bexarotene may cause a minor interaction that can limit clinical effects when taken with Verapamil
Octreotide may ... |
DB00465 | DB01191 | 886 | 1,039 | [
"DDInter1010",
"DDInter518"
] | Ketorolac | Dexfenfluramine | Ketorolac is a Non-steroidal anti-inflammatory drug (NSAID) and is commercially available as an oral tablet, injectable, nasal spray and as an ophthalmic solution. It's analgesic properties make it a useful pain management tool across many settings including postoperative pain, rheumatoid arthritis, osteoarthritis, men... | Dexfenfluramine, also marketed under the name Redux, is a serotoninergic anorectic drug. For a fairly limited time during the middle of the nineties, the US FDA had approved it for use in managing weight loss. However, following multiple concerns about the cardiovascular side-effects of the drug, such approval was with... | Moderate | 1 | [
[
[
886,
24,
1039
]
],
[
[
886,
24,
1046
],
[
1046,
63,
1039
]
],
[
[
886,
25,
500
],
[
500,
63,
1039
]
],
[
[
886,
1,
935
],
[
935,
... | [
[
[
"Ketorolac",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dexfenfluramine"
]
],
[
[
"Ketorolac",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Caplacizumab"
],
... | Ketorolac may cause a moderate interaction that could exacerbate diseases when taken with Caplacizumab and Caplacizumab may cause a moderate interaction that could exacerbate diseases when taken with Dexfenfluramine
Ketorolac may lead to a major life threatening interaction when taken with Enoxaparin and Enoxaparin may... |
DB09312 | DB06168 | 967 | 1,531 | [
"DDInter106",
"DDInter281"
] | Antithymocyte immunoglobulin (rabbit) | Canakinumab | Rabbit anti-thymocyte globulin. Thymoglobulin is a polyclonal antibody that suppresses certain types of immune cells responsible for acute organ rejection in transplant patients. Thymoglobulin is a mixture of antibodies intended to bind to various cell surface antigens. The most common mode of action of Thymoglobulin i... | Canakinumab is a recombinant, human anti-human-IL-1β monoclonal antibody that belongs to the IgG1/κ isotype subclass. It is expressed in a murine Sp2/0-Ag14 cell line and comprised of two 447- (or 448-) residue heavy chains and two 214-residue light chains, with a molecular mass of 145157 Daltons when deglycosylated. B... | Moderate | 1 | [
[
[
967,
24,
1531
]
],
[
[
967,
23,
1193
],
[
1193,
62,
1531
]
],
[
[
967,
23,
1461
],
[
1461,
23,
1531
]
],
[
[
967,
24,
1270
],
[
1270,
... | [
[
[
"Antilymphocyte immunoglobulin (horse)",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Canakinumab"
]
],
[
[
"Antilymphocyte immunoglobulin (horse)",
"{u} may cause a minor interaction that can limit clinical effects whe... | Antilymphocyte immunoglobulin (horse) may cause a moderate interaction that could exacerbate diseases when taken with Canakinumab
Antilymphocyte immunoglobulin (horse) may cause a minor interaction that can limit clinical effects when taken with Zinc gluconate and Zinc gluconate may cause a minor interaction that can l... |
DB01191 | DB06702 | 1,039 | 573 | [
"DDInter518",
"DDInter731"
] | Dexfenfluramine | Fesoterodine | Dexfenfluramine, also marketed under the name Redux, is a serotoninergic anorectic drug. For a fairly limited time during the middle of the nineties, the US FDA had approved it for use in managing weight loss. However, following multiple concerns about the cardiovascular side-effects of the drug, such approval was with... | Fesoterodine is an antimuscarinic prodrug for the treatment of overactive bladder syndrome. | Moderate | 1 | [
[
[
1039,
24,
573
]
],
[
[
1039,
62,
211
],
[
211,
1,
573
]
],
[
[
1039,
6,
12523
],
[
12523,
45,
573
]
],
[
[
1039,
63,
1018
],
[
1018,
... | [
[
[
"Dexfenfluramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fesoterodine"
]
],
[
[
"Dexfenfluramine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Tolterodine"
... | Dexfenfluramine may cause a minor interaction that can limit clinical effects when taken with Tolterodine and Tolterodine (Compound) resembles Fesoterodine (Compound)
Dexfenfluramine (Compound) binds CYP2D6 (Gene) and CYP2D6 (Gene) is bound by Fesoterodine (Compound)
Dexfenfluramine may cause a moderate interaction tha... |
DB09052 | DB11003 | 250 | 748 | [
"DDInter220",
"DDInter100"
] | Blinatumomab | Anthrax vaccine | Blinatumomab is a BiTE-class (bi-specific T-cell engager) constructed monoclonal antibody formed by the recombinant fusion of an anti-CD3 single-chain variable fragment (scFV) and an anti-CD19 scFV through a short peptide linker.[A254836,L44311] CD3 is an antigen expressed on the surface of T-cells, while CD19 is mostl... | Anthrax vaccine is a vaccine used for the pre- or post-exposure prophylaxis of disease in those at high risk of, suspected or confirmed exposure to *Bacillus anthracis*. It is subcutaneously or intramuscularly administered. It is derived from cell-free filtrates of microaerophilic cultures of an avirulent, nonencapsula... | Moderate | 1 | [
[
[
250,
24,
748
]
],
[
[
250,
63,
322
],
[
322,
24,
748
]
],
[
[
250,
25,
676
],
[
676,
63,
748
]
],
[
[
250,
64,
1057
],
[
1057,
2... | [
[
[
"Blinatumomab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Anthrax vaccine"
]
],
[
[
"Blinatumomab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Epirubicin"
],... | Blinatumomab may cause a moderate interaction that could exacerbate diseases when taken with Epirubicin and Epirubicin may cause a moderate interaction that could exacerbate diseases when taken with Anthrax vaccine
Blinatumomab may lead to a major life threatening interaction when taken with Upadacitinib and Upadacitin... |
DB00443 | DB00515 | 251 | 589 | [
"DDInter195",
"DDInter387"
] | Betamethasone | Cisplatin | Betamethasone is a long-acting corticosteroid with immunosuppressive and antiinflammatory properties. It can be used topically to manage inflammatory skin conditions such as eczema, and parenterally to manage several disease states including autoimmune disorders. Betamethasone has potent glucocorticoid activity and neg... | Cisplatin, cisplatinum or cis-diamminedichloroplatinum(II) (CDDP) is a platinum-based chemotherapy drug used to treat various types of cancers, including sarcomas, some carcinomas (e.g. small cell lung cancer, and ovarian cancer), lymphomas and germ cell tumors. It was the first member of its class, which now also incl... | Moderate | 1 | [
[
[
251,
24,
589
]
],
[
[
251,
5,
11555
],
[
11555,
44,
589
]
],
[
[
251,
7,
5566
],
[
5566,
45,
589
]
],
[
[
251,
6,
7720
],
[
7720,
... | [
[
[
"Betamethasone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cisplatin"
]
],
[
[
"Betamethasone",
"{u} (Compound) treats {v} (Disease)",
"hematologic cancer"
],
[
"hematologic cancer",
"{u} (D... | Betamethasone (Compound) treats hematologic cancer (Disease) and hematologic cancer (Disease) is treated by Cisplatin (Compound)
Betamethasone (Compound) upregulates SLC31A2 (Gene) and SLC31A2 (Gene) is bound by Cisplatin (Compound)
Betamethasone (Compound) binds PTGS2 (Gene) and PTGS2 (Gene) is bound by Cisplatin (Com... |
DB00374 | DB00834 | 1,061 | 932 | [
"DDInter1852",
"DDInter1215"
] | Treprostinil | Mifepristone | Treprostinil is a stable tricyclic analogue of prostacyclin that promotes the vasodilation of pulmonary and systemic arterial vascular beds and the inhibition of platelet aggregation.[L41855,L41860,L41865] It reduces symptoms in patients with pulmonary arterial hypertension (PAH) and pulmonary hypertension associated w... | Mifepristone is a progestational and glucocorticoid hormone antagonist. Its inhibition of progesterone induces bleeding during the luteal phase and in early pregnancy by releasing endogenous prostaglandins from the endometrium or decidua. As a glucocorticoid receptor antagonist, the drug has been used to treat hypercor... | Moderate | 1 | [
[
[
1061,
24,
932
]
],
[
[
1061,
18,
5235
],
[
5235,
46,
932
]
],
[
[
1061,
7,
7669
],
[
7669,
46,
932
]
],
[
[
1061,
18,
4071
],
[
4071,
... | [
[
[
"Treprostinil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mifepristone"
]
],
[
[
"Treprostinil",
"{u} (Compound) downregulates {v} (Gene)",
"AARS"
],
[
"AARS",
"{u} (Gene) is upregulated by ... | Treprostinil (Compound) downregulates AARS (Gene) and AARS (Gene) is upregulated by Mifepristone (Compound)
Treprostinil (Compound) upregulates DDIT4 (Gene) and DDIT4 (Gene) is upregulated by Mifepristone (Compound)
Treprostinil (Compound) downregulates PNP (Gene) and PNP (Gene) is downregulated by Mifepristone (Compou... |
DB00491 | DB01044 | 127 | 246 | [
"DDInter1217",
"DDInter809"
] | Miglitol | Gatifloxacin | Miglitol inhibits the breakdown complex carbohydrates into glucose. It is primarily used in diabetes mellitus type 2 for establishing greater glycemic control by preventing the digestion of carbohydrates (such as disaccharides, oligosaccharides, and polysaccharides) into monosaccharides which can be absorbed by the bod... | Gatifloxacin is an antibiotic agent and a member of the fourth-generation fluoroquinolone family. It works by inhibiting the bacterial enzymes DNA gyrase and topoisomerase IV. It was first introduced by Bristol-Myers Squibb in 1999 under the brand name Tequin® for the treatment of respiratory tract infections. Gatiflox... | Major | 2 | [
[
[
127,
25,
246
]
],
[
[
127,
24,
739
],
[
739,
1,
246
]
],
[
[
127,
63,
1176
],
[
1176,
1,
246
]
],
[
[
127,
24,
945
],
[
945,
40,... | [
[
[
"Miglitol",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Gatifloxacin"
]
],
[
[
"Miglitol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lomefloxacin"
],
[
"Lomefloxac... | Miglitol may cause a moderate interaction that could exacerbate diseases when taken with Lomefloxacin and Lomefloxacin (Compound) resembles Gatifloxacin (Compound)
Miglitol may cause a moderate interaction that could exacerbate diseases when taken with Moxifloxacin and Moxifloxacin (Compound) resembles Gatifloxacin (Co... |
DB00341 | DB00962 | 1,242 | 1,639 | [
"DDInter343",
"DDInter1957"
] | Cetirizine | Zaleplon | Cetirizine, also commonly known as _Zyrtec_, is an orally active second-generation histamine H1 antagonist proven effective in the treatment of various allergic symptoms, such as sneezing, coughing, nasal congestion, hives, and other symptoms,. One of the most common uses for this drug is for a condition called _allerg... | Zaleplon is a sedative/hypnotic, mainly used for insomnia. It is known as a nonbenzodiazepine hypnotic. Zaleplon interacts with the GABA receptor complex and shares some of the pharmacological properties of the benzodiazepines. Zaleplon is a schedule IV drug in the United States. | Moderate | 1 | [
[
[
1242,
24,
1639
]
],
[
[
1242,
21,
28822
],
[
28822,
60,
1639
]
],
[
[
1242,
24,
13
],
[
13,
24,
1639
]
],
[
[
1242,
24,
1532
],
[
1532... | [
[
[
"Cetirizine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Zaleplon"
]
],
[
[
"Cetirizine",
"{u} (Compound) causes {v} (Side Effect)",
"Alopecia"
],
[
"Alopecia",
"{u} (Side Effect) is caused b... | Cetirizine (Compound) causes Alopecia (Side Effect) and Alopecia (Side Effect) is caused by Zaleplon (Compound)
Cetirizine may cause a moderate interaction that could exacerbate diseases when taken with Cyproheptadine and Cyproheptadine may cause a moderate interaction that could exacerbate diseases when taken with Zal... |
DB08871 | DB13139 | 36 | 1,032 | [
"DDInter666",
"DDInter1063"
] | Eribulin | Levosalbutamol | Eribulin is a microtubule inhibitor indicated for the treatment of patients with metastatic breast cancer who have previously received at least two chemotherapeutic regimens for the treatment of metastatic disease. Eribulin was isolated from the marine sponge Halichondria okadai. Eribulin is also being investigated for... | Levosalbutamol, or levalbuterol, is a short-acting β2 adrenergic receptor agonist used in the treatment of asthma and chronic obstructive pulmonary disease (COPD). [Salbutamol] has been marketed as a racemic mixture, although beta2-agonist activity resides almost exclusively in the (R)-enantiomer. The enantioselective ... | Moderate | 1 | [
[
[
36,
24,
1032
]
],
[
[
36,
25,
1618
],
[
1618,
24,
1032
]
],
[
[
36,
24,
124
],
[
124,
24,
1032
]
],
[
[
36,
63,
594
],
[
594,
24... | [
[
[
"Eribulin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Levosalbutamol"
]
],
[
[
"Eribulin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Cabozantinib"
],
[
"Cabozant... | Eribulin may lead to a major life threatening interaction when taken with Cabozantinib and Cabozantinib may cause a moderate interaction that could exacerbate diseases when taken with Levosalbutamol
Eribulin may cause a moderate interaction that could exacerbate diseases when taken with Glasdegib and Glasdegib may caus... |
DB08865 | DB09049 | 1,593 | 1,135 | [
"DDInter448",
"DDInter1261"
] | Crizotinib | Naloxegol | Crizotinib is a tyrosine kinase receptor inhibitor used for the treatment of anaplastic lymphoma kinase (ALK) or ROS1-positive non-small cell lung cancer (NSCLC) tumors, as well as ALK-positive anaplastic large cell lymphoma (ALCL) and inflammatory myofibroblastic tumor (IMT). By targeting the echinoderm microtubule-as... | Naloxegol, for "PEGylated naloxol" is a peripherally-selective opioid antagonist developed by AstraZeneca. It was approved by the FDA in September 2014 and is indicated for the treatment of opioid-induced constipation (OIC) in adult patients with chronic non‑cancer pain. The advantage of naloxegol over the opioid antag... | Major | 2 | [
[
[
1593,
25,
1135
]
],
[
[
1593,
64,
33
],
[
33,
23,
1135
]
],
[
[
1593,
25,
1406
],
[
1406,
62,
1135
]
],
[
[
1593,
25,
1618
],
[
1618,
... | [
[
[
"Crizotinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Naloxegol"
]
],
[
[
"Crizotinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Amiodarone"
],
[
"Amiodarone",
"{u} ma... | Crizotinib may lead to a major life threatening interaction when taken with Amiodarone and Amiodarone may cause a minor interaction that can limit clinical effects when taken with Naloxegol
Crizotinib may lead to a major life threatening interaction when taken with Neratinib and Neratinib may cause a minor interaction ... |
DB00771 | DB11160 | 262 | 337 | [
"DDInter397",
"DDInter1459"
] | Clidinium | Phenyltoloxamine | Clidinium is a synthetic anticholinergic agent which has been shown in experimental and clinical studies to have a pronounced antispasmodic and antisecretory effect on the gastrointestinal tract. It inhibits muscarinic actions of acetylcholine at postganglionic parasympathetic neuroeffector sites. It is used for the tr... | Phenyltoloxamine is an antihistamine drug with sedative and analgesic effects. It is a H1 receptor blocker and a member of the ethanolamine class of antihistaminergic drugs. It is available in combination products that also contain other analgesics and antitussives such as acetaminophen. Phenyltoloxamine citrate is the... | Moderate | 1 | [
[
[
262,
24,
337
]
],
[
[
262,
24,
820
],
[
820,
24,
337
]
],
[
[
262,
63,
999
],
[
999,
24,
337
]
],
[
[
262,
74,
352
],
[
352,
24,... | [
[
[
"Clidinium",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Phenyltoloxamine"
]
],
[
[
"Clidinium",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alimemazine"
],
... | Clidinium may cause a moderate interaction that could exacerbate diseases when taken with Alimemazine and Alimemazine may cause a moderate interaction that could exacerbate diseases when taken with Phenyltoloxamine
Clidinium may cause a moderate interaction that could exacerbate diseases when taken with Thiethylperazin... |
DB08826 | DB14491 | 1,292 | 428 | [
"DDInter489",
"DDInter725"
] | Deferiprone | Ferrous fumarate | Deferiprone is an oral iron chelator used as a second line agent in thalassemia syndromes when iron overload from blood transfusions occurs. Thalassemias are a type of hereditary anaemia due a defect in the production of hemoglobin. As a result, erythropoiesis, the production of new red blood cells, is impaired. FDA ap... | Used in treatment of iron deficiency anemia. | Moderate | 1 | [
[
[
1292,
24,
428
]
],
[
[
1292,
64,
1096
],
[
1096,
23,
428
]
],
[
[
1292,
24,
1193
],
[
1193,
23,
428
]
],
[
[
1292,
24,
1384
],
[
1384,... | [
[
[
"Deferiprone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ferrous fumarate"
]
],
[
[
"Deferiprone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Mycophenolic acid"
],
[
... | Deferiprone may lead to a major life threatening interaction when taken with Mycophenolic acid and Mycophenolic acid may cause a minor interaction that can limit clinical effects when taken with Ferrous fumarate
Deferiprone may cause a moderate interaction that could exacerbate diseases when taken with Zinc gluconate a... |
DB00683 | DB09065 | 1,382 | 760 | [
"DDInter1212",
"DDInter424"
] | Midazolam | Cobicistat | Midazolam is a short-acting hypnotic-sedative drug with anxiolytic, muscle relaxant, anticonvulsant, sedative, hypnotic, and amnesic properties. It belongs to a class of drugs called _benzodiazepines_. This drug is unique from others in this class due to its rapid onset of effects and short duration of action. Midazola... | Cobicistat, marketed under the name Tybost (formerly GS-9350), indicated for treating infection with human immunodeficiency virus (HIV). Although it does not have any anti-HIV activity, cobicistat acts as a pharmacokinetic enhancer by inhibiting cytochrome P450 3A isoforms (CYP3A) and therefore increases the systemic e... | Major | 2 | [
[
[
1382,
25,
760
]
],
[
[
1382,
63,
1101
],
[
1101,
23,
760
]
],
[
[
1382,
1,
523
],
[
523,
24,
760
]
],
[
[
1382,
63,
723
],
[
723,
... | [
[
[
"Midazolam",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Cobicistat"
]
],
[
[
"Midazolam",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bexarotene"
],
[
"Bexarotene",... | Midazolam may cause a moderate interaction that could exacerbate diseases when taken with Bexarotene and Bexarotene may cause a minor interaction that can limit clinical effects when taken with Cobicistat
Midazolam (Compound) resembles Alprazolam (Compound) and Alprazolam may cause a moderate interaction that could exa... |
DB00108 | DB11714 | 1,066 | 1,316 | [
"DDInter1268",
"DDInter610"
] | Natalizumab | Durvalumab | Natalizumab is a recombinant humanized IgG4κ monoclonal antibody that binds to α4-integrin. While natalizumab was originally approved by the FDA to treat multiple sclerosis in 2004, it was withdrawn from the market following multiple reports of fatal progressive multifocal leukoencephalopathy (PML). In 2006, the FDA re... | Durvalumab is a human immunoglobulin G1 kappa (IgG1κ) monoclonal antibody and a novel immune-checkpoint inhibitor for cancer treatment. Produced by recombinant DNA technology in Chinese Hamster Ovary (CHO) cell suspension culture, durvalumab is a programmed death-ligand 1 (PD-L1) blocking antibody that works to promote... | Major | 2 | [
[
[
1066,
25,
1316
]
],
[
[
1066,
23,
1461
],
[
1461,
23,
1316
]
],
[
[
1066,
25,
167
],
[
167,
24,
1316
]
],
[
[
1066,
24,
1136
],
[
1136... | [
[
[
"Natalizumab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Durvalumab"
]
],
[
[
"Natalizumab",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Vitamin E"
],
[
"Vitamin E",... | Natalizumab may cause a minor interaction that can limit clinical effects when taken with Vitamin E and Vitamin E may cause a minor interaction that can limit clinical effects when taken with Durvalumab
Natalizumab may lead to a major life threatening interaction when taken with Hydrocortisone and Hydrocortisone may ca... |
DB00308 | DB06788 | 347 | 1,616 | [
"DDInter901",
"DDInter864"
] | Ibutilide | Histrelin | Ibutilide is a Class III antiarrhythmic agent available in intravenous formulations. It is indicated for the conversion of acute atrial flutter and recent onset atrial fibrillation to normal sinus rhythm (NSR). | Histrelin is a gonadotropin-releasing hormone (GnRH) agonist that acts as a potent inhibitor of gonadotropin when administered as an implant delivering continuous therapeutic doses. This drug is a synthetic analog of naturally occurring GnRH with a higher potency. Histrelin implants are non-biodegradable, diffusion-con... | Major | 2 | [
[
[
347,
25,
1616
]
],
[
[
347,
23,
112
],
[
112,
23,
1616
]
],
[
[
347,
25,
1342
],
[
1342,
24,
1616
]
],
[
[
347,
24,
603
],
[
603,
... | [
[
[
"Ibutilide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Histrelin"
]
],
[
[
"Ibutilide",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
[
"Metronidazol... | Ibutilide may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Histrelin
Ibutilide may lead to a major life threatening interaction when taken with Romidepsin and Romidepsin may cause a... |
DB00835 | DB01186 | 100 | 107 | [
"DDInter245",
"DDInter1430"
] | Brompheniramine | Pergolide | Histamine H1 antagonist used in treatment of allergies, rhinitis, and urticaria. | Pergolide is a long-acting dopamine agonist approved in 1982 for the treatment of Parkinson’s Disease. It is an ergot derivative that acts on the dopamine D2 and D3, alpha2- and alpha1-adrenergic, and 5-hydroxytryptamine (5-HT) receptors. It was indicated as adjunct therapy with levodopa/carbidopa in the symptomatic tr... | Moderate | 1 | [
[
[
100,
24,
107
]
],
[
[
100,
6,
12523
],
[
12523,
45,
107
]
],
[
[
100,
63,
832
],
[
832,
24,
107
]
],
[
[
100,
24,
649
],
[
649,
... | [
[
[
"Brompheniramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pergolide"
]
],
[
[
"Brompheniramine",
"{u} (Compound) binds {v} (Gene)",
"CYP2D6"
],
[
"CYP2D6",
"{u} (Gene) is bound by {v} (Co... | Brompheniramine (Compound) binds CYP2D6 (Gene) and CYP2D6 (Gene) is bound by Pergolide (Compound)
Brompheniramine may cause a moderate interaction that could exacerbate diseases when taken with Tripelennamine and Tripelennamine may cause a moderate interaction that could exacerbate diseases when taken with Pergolide
Br... |
DB00776 | DB08881 | 1,335 | 868 | [
"DDInter1360",
"DDInter1925"
] | Oxcarbazepine | Vemurafenib | Oxcarbazepine is an anti-epileptic medication used in the treatment of partial onset seizures that was first approved for use in the United States in 2000.[L8627,L8630,L8633] It is a structural derivative of [carbamazepine] and exerts a majority of its activity via a pharmacologically active metabolite, MHD, which exis... | Vemurafenib is a competitive kinase inhibitor with activity against BRAF kinase with mutations like V600E. It exerts its function by binding to the ATP-binding domain of the mutant BRAF. Vemurafenib was co-developed by Roche and Plexxikon and it obtained its FDA approval on August 17, 2011, under the company Hoffmann L... | Moderate | 1 | [
[
[
1335,
24,
868
]
],
[
[
1335,
6,
8374
],
[
8374,
45,
868
]
],
[
[
1335,
18,
3385
],
[
3385,
57,
868
]
],
[
[
1335,
21,
29015
],
[
29015... | [
[
[
"Oxcarbazepine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vemurafenib"
]
],
[
[
"Oxcarbazepine",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Comp... | Oxcarbazepine (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Vemurafenib (Compound)
Oxcarbazepine (Compound) downregulates SDC1 (Gene) and SDC1 (Gene) is downregulated by Vemurafenib (Compound)
Oxcarbazepine (Compound) causes Eosinophilia (Side Effect) and Eosinophilia (Side Effect) is caused by Vemurafen... |
DB00635 | DB09420 | 1,573 | 1,074 | [
"DDInter1515",
"DDInter953"
] | Prednisone | Iodide I-123 | A synthetic anti-inflammatory glucocorticoid derived from [cortisone]. It is biologically inert and converted to [prednisolone] in the liver. Prednisone was granted FDA approval on 21 February 1955. | Iodide I-123 (as sodium Iodide I-123) is a radioactive isotope of iodine used in nuclear medicine for the diagnostic study of thyroid disease. Following oral administration, I-123 is absorbed through the gastrointestinal tract and is taken up by the thyroid gland. After incorporation, a gamma camera is used to detect t... | Moderate | 1 | [
[
[
1573,
24,
1074
]
],
[
[
1573,
24,
1004
],
[
1004,
63,
1074
]
],
[
[
1573,
62,
523
],
[
523,
24,
1074
]
],
[
[
1573,
24,
126
],
[
126,
... | [
[
[
"Prednisone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Iodide I-123"
]
],
[
[
"Prednisone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Phenyl salicylate"
],... | Prednisone may cause a moderate interaction that could exacerbate diseases when taken with Phenyl salicylate and Phenyl salicylate may cause a moderate interaction that could exacerbate diseases when taken with Iodide I-123
Prednisone may cause a minor interaction that can limit clinical effects when taken with Alprazo... |
DB00976 | DB08865 | 1,056 | 1,593 | [
"DDInter1758",
"DDInter448"
] | Telithromycin | Crizotinib | Telithromycin, a semi-synthetic erythromycin derivative, belongs to a new chemical class of antibiotics called ketolides. Ketolides have been recently added to the macrolide-lincosamide-streptogramin class of antibiotics. Similar to the macrolide antibiotics, telithromycin prevents bacterial growth by interfering with ... | Crizotinib is a tyrosine kinase receptor inhibitor used for the treatment of anaplastic lymphoma kinase (ALK) or ROS1-positive non-small cell lung cancer (NSCLC) tumors, as well as ALK-positive anaplastic large cell lymphoma (ALCL) and inflammatory myofibroblastic tumor (IMT). By targeting the echinoderm microtubule-as... | Major | 2 | [
[
[
1056,
25,
1593
]
],
[
[
1056,
6,
8374
],
[
8374,
45,
1593
]
],
[
[
1056,
21,
29093
],
[
29093,
60,
1593
]
],
[
[
1056,
25,
283
],
[
28... | [
[
[
"Telithromycin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Crizotinib"
]
],
[
[
"Telithromycin",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
"C... | Telithromycin (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Crizotinib (Compound)
Telithromycin (Compound) causes Fatigue (Side Effect) and Fatigue (Side Effect) is caused by Crizotinib (Compound)
Telithromycin may lead to a major life threatening interaction when taken with Fedratinib and Fedratinib may... |
DB09330 | DB14409 | 985 | 1,129 | [
"DDInter1352",
"DDInter867"
] | Osimertinib | Human adenovirus e serotype 4 strain cl-68578 antigen | Osimertinib is an oral, third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) drug developed by AstraZeneca Pharmaceuticals.[A7926,L43453] Its use is indicated for the treatment of metastatic non-small cell lung cancer (NSCLC) in cases where tumour EGFR expression is positive for the ... | Human adenovirus e serotype 4 strain cl-68578 antigen is a vaccine. | Moderate | 1 | [
[
[
985,
24,
1129
]
],
[
[
985,
64,
1057
],
[
1057,
24,
1129
]
],
[
[
985,
63,
1683
],
[
1683,
24,
1129
]
],
[
[
985,
24,
119
],
[
119,
... | [
[
[
"Osimertinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Human adenovirus e serotype 4 strain cl-68578 antigen"
]
],
[
[
"Osimertinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
... | Osimertinib may lead to a major life threatening interaction when taken with Etanercept and Etanercept may cause a moderate interaction that could exacerbate diseases when taken with Human adenovirus e serotype 4 strain cl-68578 antigen
Osimertinib may cause a moderate interaction that could exacerbate diseases when ta... |
DB00242 | DB08868 | 1,064 | 1,011 | [
"DDInter392",
"DDInter737"
] | Cladribine | Fingolimod | An antineoplastic agent used in the treatment of lymphoproliferative diseases including hairy-cell leukemia. | Multiple sclerosis, or MS, is a devastating inflammatory disease that often progresses and causes severe neurological, physical, and cognitive effects. Fingolimod is a sphingosine 1-phosphate receptor modulator for the treatment of relapsing-remitting multiple sclerosis. It was developed by Novartis and initially appro... | Major | 2 | [
[
[
1064,
25,
1011
]
],
[
[
1064,
5,
11594
],
[
11594,
44,
1011
]
],
[
[
1064,
21,
28792
],
[
28792,
60,
1011
]
],
[
[
1064,
24,
748
],
[
... | [
[
[
"Cladribine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Fingolimod"
]
],
[
[
"Cladribine",
"{u} (Compound) treats {v} (Disease)",
"multiple sclerosis"
],
[
"multiple sclerosis",
"{u} (Disease) is treated b... | Cladribine (Compound) treats multiple sclerosis (Disease) and multiple sclerosis (Disease) is treated by Fingolimod (Compound)
Cladribine (Compound) causes Gastrointestinal disorder (Side Effect) and Gastrointestinal disorder (Side Effect) is caused by Fingolimod (Compound)
Cladribine may cause a moderate interaction t... |
DB00501 | DB01611 | 752 | 1,487 | [
"DDInter380",
"DDInter893"
] | Cimetidine | Hydroxychloroquine | A histamine congener, it competitively inhibits histamine binding to histamine H2 receptors. Cimetidine has a range of pharmacological actions. It inhibits gastric acid secretion, as well as pepsin and gastrins output. It also blocks the activity of cytochrome P-450 which might explain proposals for use in neoadjuvant ... | Hydroxychloroquine is a racemic mixture consisting of an R and S enantiomer. Hydroxychloroquine is an aminoquinoline like [chloroquine]. It is a commonly prescribed medication in the treatment of uncomplicated malaria, rheumatoid arthritis, chronic discoid lupus erythematosus, and systemic lupus erythematosus. Hydroxyc... | Moderate | 1 | [
[
[
752,
24,
1487
]
],
[
[
752,
6,
12523
],
[
12523,
45,
1487
]
],
[
[
752,
21,
28658
],
[
28658,
60,
1487
]
],
[
[
752,
24,
211
],
[
211,... | [
[
[
"Cimetidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Hydroxychloroquine"
]
],
[
[
"Cimetidine",
"{u} (Compound) binds {v} (Gene)",
"CYP2D6"
],
[
"CYP2D6",
"{u} (Gene) is bound by {v} (Com... | Cimetidine (Compound) binds CYP2D6 (Gene) and CYP2D6 (Gene) is bound by Hydroxychloroquine (Compound)
Cimetidine (Compound) causes Vomiting (Side Effect) and Vomiting (Side Effect) is caused by Hydroxychloroquine (Compound)
Cimetidine may cause a moderate interaction that could exacerbate diseases when taken with Tolte... |
DB00222 | DB00491 | 245 | 127 | [
"DDInter825",
"DDInter1217"
] | Glimepiride | Miglitol | First introduced in 1995, glimepiride is a member of the second-generation sulfonylurea (SU) drug class used for the management of type 2 diabetes mellitus (T2DM) to improve glycemic control. Type 2 diabetes is a metabolic disorder with increasing prevalences worldwide; it is characterized by insulin resistance in acco... | Miglitol inhibits the breakdown complex carbohydrates into glucose. It is primarily used in diabetes mellitus type 2 for establishing greater glycemic control by preventing the digestion of carbohydrates (such as disaccharides, oligosaccharides, and polysaccharides) into monosaccharides which can be absorbed by the bod... | Moderate | 1 | [
[
[
245,
24,
127
]
],
[
[
245,
5,
11640
],
[
11640,
44,
127
]
],
[
[
245,
21,
29180
],
[
29180,
60,
127
]
],
[
[
245,
23,
721
],
[
721,
... | [
[
[
"Glimepiride",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Miglitol"
]
],
[
[
"Glimepiride",
"{u} (Compound) treats {v} (Disease)",
"type 2 diabetes mellitus"
],
[
"type 2 diabetes mellitus",
... | Glimepiride (Compound) treats type 2 diabetes mellitus (Disease) and type 2 diabetes mellitus (Disease) is treated by Miglitol (Compound)
Glimepiride (Compound) causes Abdominal distension (Side Effect) and Abdominal distension (Side Effect) is caused by Miglitol (Compound)
Glimepiride may cause a minor interaction tha... |
DB06605 | DB14568 | 1,409 | 982 | [
"DDInter108",
"DDInter1000"
] | Apixaban | Ivosidenib | Apixaban is an oral, direct, and highly selective factor Xa (FXa) inhibitor of both free and bound FXa, as well as prothrombinase, independent of antithrombin III for the prevention and treatment of thromboembolic diseases[Label,A6897]. It is marketed under the name Eliquis[Label,L6043]. Apixaban was approved by the FD... | Ivosidenib is a first-in-class isocitrate dehydrogenase-1 (IDH1) inhibitor. IDH1 is an enzyme that is often mutated and overexpressed in some cancers, leading to aberrant cell growth and proliferation. Ivosidenib inhibits mutated IDH1, blocking the enzymatic activity and further differentiation of cancer cells. Ivoside... | Moderate | 1 | [
[
[
1409,
24,
982
]
],
[
[
1409,
63,
1101
],
[
1101,
23,
982
]
],
[
[
1409,
24,
241
],
[
241,
24,
982
]
],
[
[
1409,
25,
503
],
[
503,
... | [
[
[
"Apixaban",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ivosidenib"
]
],
[
[
"Apixaban",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bexarotene"
],
[
... | Apixaban may cause a moderate interaction that could exacerbate diseases when taken with Bexarotene and Bexarotene may cause a minor interaction that can limit clinical effects when taken with Ivosidenib
Apixaban may cause a moderate interaction that could exacerbate diseases when taken with Erdafitinib and Erdafitinib... |
DB06335 | DB09054 | 761 | 384 | [
"DDInter1646",
"DDInter905"
] | Saxagliptin | Idelalisib | Saxagliptin (rINN) is an orally active hypoglycemic (anti-diabetic drug) of the new dipeptidyl peptidase-4 (DPP-4) inhibitor class of drugs. FDA approved on July 31, 2009. | Idelalisib is a phosphoinositide 3-kinase inhibitor indicated in the treatment of chronic lymphocytic leukemia (CLL), relapsed follicular B-cell non-Hodgkin lymphoma (FL), and relapsed small lymphocytic lymphoma (SLL). For the treatment of relapsed CLL, it is currently indicated as a second-line agent in combination wi... | Moderate | 1 | [
[
[
761,
24,
384
]
],
[
[
761,
63,
222
],
[
222,
23,
384
]
],
[
[
761,
24,
555
],
[
555,
23,
384
]
],
[
[
761,
62,
307
],
[
307,
23,... | [
[
[
"Saxagliptin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Idelalisib"
]
],
[
[
"Saxagliptin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sibutramine"
],
[... | Saxagliptin may cause a moderate interaction that could exacerbate diseases when taken with Sibutramine and Sibutramine may cause a minor interaction that can limit clinical effects when taken with Idelalisib
Saxagliptin may cause a moderate interaction that could exacerbate diseases when taken with Netupitant and Netu... |
DB00857 | DB08880 | 1,387 | 1,510 | [
"DDInter1768",
"DDInter1771"
] | Terbinafine | Teriflunomide | Terbinafine hydrochloride (Lamisil) is a synthetic allylamine antifungal.[L9065,L9068] It is highly lipophilic in nature and tends to accumulate in skin, nails, and fatty tissues. Like other allylamines, terbinafine inhibits ergosterol synthesis by inhibiting the fungal squalene monooxygenase (also called squalene epox... | Teriflunomide is the active metabolite of leflunomide, and it acts as an immunomodulatory agent by inhibiting pyrimidine synthesis. It is marketed under the name Aubagio® and is indicated for the treatment of multiple sclerosis, specifically relapsing forms. The FDA label states an important warning about the risk of h... | Major | 2 | [
[
[
1387,
25,
1510
]
],
[
[
1387,
24,
129
],
[
129,
63,
1510
]
],
[
[
1387,
63,
1031
],
[
1031,
24,
1510
]
],
[
[
1387,
62,
1684
],
[
1684... | [
[
[
"Terbinafine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Teriflunomide"
]
],
[
[
"Terbinafine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Enzalutamide"
],
[
"Enz... | Terbinafine may cause a moderate interaction that could exacerbate diseases when taken with Enzalutamide and Enzalutamide may cause a moderate interaction that could exacerbate diseases when taken with Teriflunomide
Terbinafine may cause a moderate interaction that could exacerbate diseases when taken with Theophylline... |
DB01309 | DB14006 | 1,254 | 972 | [
"DDInter933",
"DDInter370"
] | Insulin glulisine | Choline salicylate | Insulin glulisine is a short-acting form of insulin used for the treatment of hyperglycemia caused by Type 1 and Type 2 Diabetes. Insulin is typically prescribed for the management of diabetes mellitus to mimic the activity of endogenously produced human insulin, a peptide hormone produced by beta cells of the pancreas... | Choline salicylate is an anti-inflammatory pain reliever agent that is related to aspirin. It is used to decrease swelling and to treat mild-moderate pain. It is used to treat arthritis in both children and adults. This medicine can also be used for fever . Choline Salicylate is the choline salt of salicylic acid, used... | Moderate | 1 | [
[
[
1254,
24,
972
]
],
[
[
1254,
63,
1573
],
[
1573,
24,
972
]
],
[
[
1254,
24,
1019
],
[
1019,
24,
972
]
],
[
[
1254,
63,
1573
],
[
1573,... | [
[
[
"Insulin glulisine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Choline salicylate"
]
],
[
[
"Insulin glulisine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Predn... | Insulin glulisine may cause a moderate interaction that could exacerbate diseases when taken with Prednisone and Prednisone may cause a moderate interaction that could exacerbate diseases when taken with Choline salicylate
Insulin glulisine may cause a moderate interaction that could exacerbate diseases when taken with... |
DB00197 | DB01579 | 1,324 | 341 | [
"DDInter1881",
"DDInter1439"
] | Troglitazone | Phendimetrazine | Troglitazone was withdrawn in 2000 due to risk of hepatotoxicity. It was superseded by [pioglitazone] and [rosiglitazone]. | Phendimetrazine is a weight loss medication. Phendimetrazine is chemically related to amphetamines and is a Schedule III drug under the Convention on Psychotropic Substances and in the US since 1970. | Moderate | 1 | [
[
[
1324,
24,
341
]
],
[
[
1324,
24,
1281
],
[
1281,
63,
341
]
],
[
[
1324,
24,
401
],
[
401,
24,
341
]
],
[
[
1324,
63,
1179
],
[
1179,
... | [
[
[
"Troglitazone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Phendimetrazine"
]
],
[
[
"Troglitazone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Linagliptin"
]... | Troglitazone may cause a moderate interaction that could exacerbate diseases when taken with Linagliptin and Linagliptin may cause a moderate interaction that could exacerbate diseases when taken with Phendimetrazine
Troglitazone may cause a moderate interaction that could exacerbate diseases when taken with Promethazi... |
DB00358 | DB00816 | 1,010 | 1,674 | [
"DDInter1140",
"DDInter1346"
] | Mefloquine | Orciprenaline | Malaria is a protozoan disease that places an enormous burden on human health in endemic areas around the world. The 2020 World Health Organization malaria report indicates a 60% decrease in the global malaria fatality rate between 2000 to 2019. Despite this, malaria remains a significant cause of morbidity and mortali... | A beta-adrenergic agonist used in the treatment of asthma and bronchospasms. [PubChem] | Moderate | 1 | [
[
[
1010,
24,
1674
]
],
[
[
1010,
7,
3222
],
[
3222,
46,
1674
]
],
[
[
1010,
21,
28921
],
[
28921,
60,
1674
]
],
[
[
1010,
24,
1220
],
[
1... | [
[
[
"Mefloquine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Orciprenaline"
]
],
[
[
"Mefloquine",
"{u} (Compound) upregulates {v} (Gene)",
"DUSP4"
],
[
"DUSP4",
"{u} (Gene) is upregulated by {v}... | Mefloquine (Compound) upregulates DUSP4 (Gene) and DUSP4 (Gene) is upregulated by Orciprenaline (Compound)
Mefloquine (Compound) causes Dizziness (Side Effect) and Dizziness (Side Effect) is caused by Orciprenaline (Compound)
Mefloquine may cause a moderate interaction that could exacerbate diseases when taken with Dex... |
DB00220 | DB01166 | 798 | 477 | [
"DDInter1276",
"DDInter379"
] | Nelfinavir | Cilostazol | Nelfinavir is a potent HIV-1 protease inhibitor. It is used in combination with other antiviral drugs in the treatment of HIV in both adults and children. Nelfinavir inhibits the HIV viral proteinase enzyme which prevents cleavage of the gag-pol polyprotein, resulting in noninfectious, immature viral particles. | Cilostazol is a quinolinone derivative and antiplatelet agent with vasodilating properties that has been used in the symptomatic treatment of intermittent claudication in patients with peripheral ischaemia. It is marketed under the brand name Pletal by Otsuka Pharmaceutical Co.. Cilostazol works by inhibiting both prim... | Major | 2 | [
[
[
798,
25,
477
]
],
[
[
798,
6,
8374
],
[
8374,
45,
477
]
],
[
[
798,
7,
9384
],
[
9384,
57,
477
]
],
[
[
798,
21,
28919
],
[
28919,
... | [
[
[
"Nelfinavir",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Cilostazol"
]
],
[
[
"Nelfinavir",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
"Cilosta... | Nelfinavir (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Cilostazol (Compound)
Nelfinavir (Compound) upregulates TRIB3 (Gene) and TRIB3 (Gene) is downregulated by Cilostazol (Compound)
Nelfinavir (Compound) causes Arthritis (Side Effect) and Arthritis (Side Effect) is caused by Cilostazol (Compound)
Nelf... |
DB00963 | DB08870 | 1,263 | 850 | [
"DDInter241",
"DDInter228"
] | Bromfenac | Brentuximab vedotin | Bromfenac is a nonsteroidal anti-inflammatory drug (NSAID) for ophthalmic use. Ophthalmic NSAIDs are becoming a cornerstone for the management of ocular pain and inflammation. Their well-characterized anti-inflammatory activity, analgesic property, and established safety record have also made NSAIDs an important tool f... | Brentuximab vedotin, also known as Adcetris®, is an antibody-drug conjugate that combines an anti-CD30 antibody with the drug monomethyl auristatin E (MMAE). It is an anti-neoplastic agent used in the treatment of Hodgkin's lymphoma and systemic anaplastic large-cell lymphoma. Brentuximab vedotin was initially approved... | Moderate | 1 | [
[
[
1263,
24,
850
]
],
[
[
1263,
63,
267
],
[
267,
24,
850
]
],
[
[
1263,
25,
1468
],
[
1468,
63,
850
]
],
[
[
1263,
25,
39
],
[
39,
... | [
[
[
"Bromfenac",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Brentuximab vedotin"
]
],
[
[
"Bromfenac",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Naltrexone"
],
... | Bromfenac may cause a moderate interaction that could exacerbate diseases when taken with Naltrexone and Naltrexone may cause a moderate interaction that could exacerbate diseases when taken with Brentuximab vedotin
Bromfenac may lead to a major life threatening interaction when taken with Ponatinib and Ponatinib may c... |
DB00069 | DB00773 | 367 | 896 | [
"DDInter946",
"DDInter702"
] | Interferon alfacon-1 | Etoposide | Interferon alfacon-1 is a recombinant non-naturally occurring type-I interferon. The 166-amino acid sequence of Interferon alfacon-1 was derived by scanning the sequences of several natural interferon alpha subtypes and assigning the most frequently observed amino acid in each corresponding position. Four additional am... | A semisynthetic derivative of podophyllotoxin that exhibits antitumor activity. Etoposide inhibits DNA synthesis by forming a complex with topoisomerase II and DNA. This complex induces breaks in double stranded DNA and prevents repair by topoisomerase II binding. Accumulated breaks in DNA prevent entry into the mitoti... | Moderate | 1 | [
[
[
367,
24,
896
]
],
[
[
367,
24,
147
],
[
147,
23,
896
]
],
[
[
367,
24,
700
],
[
700,
63,
896
]
],
[
[
367,
25,
1477
],
[
1477,
6... | [
[
[
"Interferon alfacon-1",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Etoposide"
]
],
[
[
"Interferon alfacon-1",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vinblast... | Interferon alfacon-1 may cause a moderate interaction that could exacerbate diseases when taken with Vinblastine and Vinblastine may cause a minor interaction that can limit clinical effects when taken with Etoposide
Interferon alfacon-1 may cause a moderate interaction that could exacerbate diseases when taken with At... |
DB00490 | DB08899 | 946 | 129 | [
"DDInter254",
"DDInter649"
] | Buspirone | Enzalutamide | Buspirone is a novel anxiolytic agent with a unique structure and a pharmacological profile. Belonging to the azaspirodecanedione drug class, buspirone is a serotonin 5-HT<sub>1A</sub> receptor agonist that is not chemically or pharmacologically related to benzodiazepines, barbiturates, and other sedative/anxiolytic dr... | Enzalutamide is an androgen receptor (AR) inhibitor for the treatment of castration-resistant prostate cancer (CRPC), both metastatic and non-metastatic. It is a second-generation antiandrogen agent that the FDA approved on August 31, 2012.[L40639, A252667] Although androgen deprivation therapy (ADT) is the first-line ... | Major | 2 | [
[
[
946,
25,
129
]
],
[
[
946,
6,
8374
],
[
8374,
45,
129
]
],
[
[
946,
21,
28703
],
[
28703,
60,
129
]
],
[
[
946,
24,
1320
],
[
1320,
... | [
[
[
"Buspirone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Enzalutamide"
]
],
[
[
"Buspirone",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
"Enzalut... | Buspirone (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Enzalutamide (Compound)
Buspirone (Compound) causes Pruritus (Side Effect) and Pruritus (Side Effect) is caused by Enzalutamide (Compound)
Buspirone may cause a moderate interaction that could exacerbate diseases when taken with Elagolix and Elagoli... |
DB01128 | DB06626 | 918 | 263 | [
"DDInter204",
"DDInter147"
] | Bicalutamide | Axitinib | Bicalutamide is an oral non-steroidal anti-androgen for prostate cancer. It is comprised of a racemic mixture that is a 50:50 composition of the (R)-bicalutamide and (S)-bicalutamide enantionmers. Bicalutamide binds to the androgen receptor. | Axitinib is a second generation tyrosine kinase inhibitor that works by selectively inhibiting vascular endothelial growth factor receptors (VEGFR-1, VEGFR-2, VEGFR-3). Through this mechanism of action, axitinib blocks angiogenesis, tumour growth and metastases. It is reported to exhibit potency that is 50-450 times hi... | Moderate | 1 | [
[
[
918,
24,
263
]
],
[
[
918,
63,
1559
],
[
1559,
23,
263
]
],
[
[
918,
24,
286
],
[
286,
62,
263
]
],
[
[
918,
63,
322
],
[
322,
2... | [
[
[
"Bicalutamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Axitinib"
]
],
[
[
"Bicalutamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Famotidine"
],
[
... | Bicalutamide may cause a moderate interaction that could exacerbate diseases when taken with Famotidine and Famotidine may cause a minor interaction that can limit clinical effects when taken with Axitinib
Bicalutamide may cause a moderate interaction that could exacerbate diseases when taken with Magnesium hydroxide a... |
DB00285 | DB06754 | 1,100 | 707 | [
"DDInter1927",
"DDInter471"
] | Venlafaxine | Danaparoid | Venlafaxine is an antidepressant and a serotonin and norepinephrine reuptake inhibitor (SNRI). Its active metabolite, [desvenlafaxine], works by blocking the reuptake of serotonin and norepinephrine, which are key neurotransmitters in mood regulation. Venlafaxine is officially approved to treat major depressive disorde... | Danaparoid is a low-molecular-weight heparinoid with an average molecular weight of 5500 Daltons consisting of a mixture of glycosaminoglycans . The active constituents are heparan, dermatan and , and they are isolated from the porcine intestinal mucosa [FDA Label]. Danaparoid possesses a potent antithrombic activity t... | Moderate | 1 | [
[
[
1100,
24,
707
]
],
[
[
1100,
25,
121
],
[
121,
24,
707
]
],
[
[
1100,
24,
1151
],
[
1151,
24,
707
]
],
[
[
1100,
1,
643
],
[
643,
... | [
[
[
"Venlafaxine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Danaparoid"
]
],
[
[
"Venlafaxine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Fenfluramine"
],
[
"Fenflu... | Venlafaxine may lead to a major life threatening interaction when taken with Fenfluramine and Fenfluramine may cause a moderate interaction that could exacerbate diseases when taken with Danaparoid
Venlafaxine may cause a moderate interaction that could exacerbate diseases when taken with Sunitinib and Sunitinib may ca... |
DB01618 | DB09488 | 776 | 103 | [
"DDInter1239",
"DDInter23"
] | Molindone | Acrivastine | An indole derivative effective in schizophrenia and other psychoses and possibly useful in the treatment of the aggressive type of undersocialized conduct disorder. Molindone has much lower affinity for D2 receptors than most antipsychotic agents and has a relatively low affinity for D1 receptors. It has only low to mo... | Acrivastine is a triprolidine analog antihistamine indicated for the treatment of allergies and hay fever. As an H1 receptor antagonist, it functions by blocking the action of histamine at this receptor thereby preventing the symptoms associated with histamine release such as pruritis, vasodilation, hypotension, edema,... | Moderate | 1 | [
[
[
776,
24,
103
]
],
[
[
776,
63,
85
],
[
85,
24,
103
]
],
[
[
776,
24,
830
],
[
830,
24,
103
]
],
[
[
776,
64,
1621
],
[
1621,
25,... | [
[
[
"Molindone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Acrivastine"
]
],
[
[
"Molindone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Atropine"
],
[
... | Molindone may cause a moderate interaction that could exacerbate diseases when taken with Atropine and Atropine may cause a moderate interaction that could exacerbate diseases when taken with Acrivastine
Molindone may cause a moderate interaction that could exacerbate diseases when taken with Phenindamine and Phenindam... |
DB01131 | DB05541 | 1,243 | 801 | [
"DDInter1531",
"DDInter239"
] | Proguanil | Brivaracetam | Proguanil is a prophylactic antimalarial drug, which works by stopping the malaria parasite, _Plasmodium falciparum_ and _Plasmodium vivax_, from reproducing once it is in the red blood cells. It does this by inhibiting the enzyme, dihydrofolate reductase, which is involved in the reproduction of the parasite. | Brivaracetam is a racetam derivative of levetiracetam used in the treatment of partial-onset seizures. Brivaracetam binds SV2A with 20 times higher affinity than levetiracetam . It is available under the brand name Briviact made by UCB. Briviact received FDA approval on February 19, 2016 . | Minor | 0 | [
[
[
1243,
23,
801
]
],
[
[
1243,
63,
126
],
[
126,
23,
801
]
],
[
[
1243,
6,
8374
],
[
8374,
45,
477
],
[
477,
23,
801
]
],
[
[
1243,
... | [
[
[
"Proguanil",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Brivaracetam"
]
],
[
[
"Proguanil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Warfarin"
],
[
... | Proguanil may cause a moderate interaction that could exacerbate diseases when taken with Warfarin and Warfarin may cause a minor interaction that can limit clinical effects when taken with Brivaracetam
Proguanil (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Cilostazol (Compound) and Cilostazol may cause... |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.